Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1985

Exercise induced bronchospasm and the effect of
ascorbic acid : a study of the possible role of
prostaglandins
Greg A. Sachs
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Sachs, Greg A., "Exercise induced bronchospasm and the effect of ascorbic acid : a study of the possible role of prostaglandins" (1985).
Yale Medicine Thesis Digital Library. 3119.
http://elischolar.library.yale.edu/ymtdl/3119

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

YALE

MEDICAL LIBRARY

Permission for photocopying or microfilming of "
X/iUrtna-hosct*A

t^e

£^^

Effect

Asceth;c

(title of thesis)

Ac'id'* A

&£ +~h<t f&>s.%rbj& ?kc /<?

cf*

P^

"

for the purpose of individual scholarly consultation or refer¬
ence is hereby granted by the author.

This permission is not

to be interpreted as affecting publication of this work, or
otherwise placing it in the public domain, and the author re¬
serves all rights of ownership guaranteed under common law
protection of unpublished manuscripts.

V

a. Xx

(Signature of author)
At-

ivs'

(Printed name)

3/sr/
(Date)

■

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/exerciseinducedbOOsach

EXERCISE INDUCED BRONCHOSPASM AND
THE EFFECT OF ASCORBIC ACID:
A STUDY OF THE POSSIBLE ROLE OF PROSTAGLANDINS

by

GREG A.

SACHS

A thesis submitted to the
Yale University School of Medicine
in partial fulfillment of the
requirements for the degree of
Doctor of Medicine

1985

6977

ABSTRACT

The role of ascorbic acid in
Ascorbic acid

the treatment of asthma remains undefined.

has previously

been associated

against a number of asthmatic reactions.
to modify

prostaglandin synthesis a study

possible role of prostaglandins in

with partial

protection

Since this agent is also known
was designed to

examine the

exercise induced bronchospasm (EIB).

Twelve subjects were recruited on the basis of a history consistent with
EIB and the demonstration of a 20%

decrease from baseline in MEF40% (P)

during a preliminary exercise trial.
subjects ingested either:
cin,

On

four subsequent test days the

(1) 750 mg ascorbic acid,

(3) 750 mg ascorbic acid plus 50 mg indomethacin, or (4) a placebo.

These substances were given in a double-blind,
shion.

randomized, crossover fa¬

Exercise challenge with pulmonary function testing was performed

on each drug day.
strate the

For the group as a whole this

previously described

Neither indomethacin alone

attenuation of

theless,

study did not demon¬
EIB by

or in combination with

enced the post-exercise bronchoconsriction seen

ascorbic acid.

ascorbic acid influ¬

in this group.

Never¬

three subjects did demonstrate a consistent attenuation of EIB

following treatment with

ascorbic acid.

sponders" could be separated
lower

(2) 50 mg indometha-

baseline FEV1

The three

"ascorbic acid re¬

from the other subjects on the

(expressed

as percent

of

basis of a

the predicted

value).

These and previous observations suggest that the effect of ascorbic acid
in EIB may occur only in a subgroup of patients with EIB.
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I
EXERCISE INDUCED BRONCHOSPASM

Exercise induced bronchospasm is a phenomenon that was described as ear¬
ly as the first century A.D. when Aretaeus the Cappadocian noted the as¬
sociation between strenuous
ams,

1856).

medicine,

This

exercise and acute airway

association,

like many such

was to be redescribed hundreds

John Floyer

not only redescribed

obstruction (Ad¬

early observations in

of years later.

exercise induced

In 1698 Sir

bronchospasm (EIB),

but also pointed out that tasks having the highest levels of ventilation
seemed to

provoke the most

severe wheezing (Floyer,

1698).

Neither

Floyer nor other researchers in the next two hundred and fifty years ap¬
preciated the full significance of this observation.
Henry Hyde Salter, yet another keen observer whose thoughts were not
appreciated until recently,

recognized in 1864 that EIB was exacerbated

by exercising in a cold environment (Salter,
In 1946 Herxheimer performed the
ured

changes in

1946).

function in

first study that objectively meas¬
response

Herxheimer measured the change

after exercise and
in EIB.

lung

1864).

to exercise

(Herxheimer,

in vital capacity of asthmatics

postulated that hyperventilation was

the key factor

A great deal of research was sparked by Herxheimer's findings.

However, confusion and controversy surrounded this work on EIB.
The first point of contention arose
(Capel,

1959) and Engstrom (Engstrom,

1

from studies by Capel and Smart

1960) which, unlike previous stud-

2
ies,

demonstrated

an increase in

FEV1

and lung compliance and

crease in airway resistance in asthmatics

after exercise.

believed that this apparent variability in
to differences

in the duration and

different studies.

Jones et al

response to exercise was due

intensity of the exercise

in these

He showed that this was indeed the case, as asthmat¬

ic children exercising
in FEV1,

a de¬

for less than two minutes had

a slight increase

while those exercising for between eight and ten minutes had a

consistent decrease in FEV1 after exercise (Jones,
This initial confusion illustrates the

1962).

principal sources of contro¬

versy in EIB research which for many years arose from the variability of
the exercise challenges (type of exercise, duration, and intensity)
pulmonary function tests used to
have included swimming (Fitch,

study EIB.
1971),

These exercise challenges

stairclimbing (McNeill,

free running (Jones, 1966), treadmill running (Sly,
on a cycloergometer (Pierson,

1970).

sponse to exercise include FVC and
1963), PEFR (Sly,

1970),

and

1970),

1966),

and cycling

Parameters used to measure the re¬
TLC (Anderson,

1972),

FEV1

(Jones,

maximal mid-expiratory flow rates (MMEFR)

airway resistance or conductance (Haynes,

1976),

and

as well as flow rates

at low lung volumes on MEFV and PEFV curves (Schachter,

1978a).

Given

the variability of the challenge from study to study, as well as differ¬
ences in the severity of the asthma of the subjects studied,
to see how estimates of the prevalence

it is easy

of EIB in asthmatics have ranged

from nineteen percent (Cropp, 1975) to as high as ninety percent (Kiviloog, 1975).

The difficulty of studying the mechanism of EIB under such

conditions can also be appreciated.

3
The issue of which parameters are
rate has been addressed by Bouhuys.
ditional PFTs (such as

the most sensitive and most accu¬
Bouhuys observed that the more tra¬

FEV1 and PEFR)

are not very

sensitive to small

changes in airway caliber and, moreover, are affected by the effort made
by the subject performing the maneuver.
a study by

Pride which shows that

These concepts are supported by

subjects are able to

quate PEFR even with significant obstruction
adequate and ample effort is made

(Pride,

also demonstrated that a deep inspiration,
ing a MEFV curve,
(Lloyd,

attain an ade¬

if their vital capacity is
1971).

Other workers have

such as that made in generat¬

could by itself lead to transient bronchoconstriction

1963 and Nadel, 1961).

Bouhuys was able to show that this dif¬

ficulty could be avoided by using flow

rates on PEFV curves,

maneuver is made from only a partial inspiration (Bouhuys,
Bouhuys advocated the measurement of
lung volumes: MEF40% and MEF40%(P)
ments in

1978 Schachter

instantaneous

(Bouhuys,

et al were

1976).

able to

asthmatics the MEF40%(P)

was the

EIB (Schachter,

In Schachter's study,

1978a).

crease in a parameter as

since the

1969).

Thus,

flow rates at lower
Using such measure¬

demonstrate that

in mild

most sensitive parameter in detecting

a significant response,

using a ten percent de¬
MEF40%(P)

identified

EIB in sixteen of nineteen asthmatics,

while none of the seven nonasth¬

matic controls were shown to have EIB.

Only seven of the nineteen asth¬

matics would have been identified as having EIB if a ten percent drop in
FEV1 had been used as the

defining parameter.

PEFV curves at low lung volumes are
choconstriction.

Thus,

parameters using

sensitive to small degrees of bron¬

4
The other type of pulmonary function
tensively in

testing that has been used ex¬

measuring bronchoconstriction

is volume

displacement

body plethysmography and the determination

of airway resistance or spe¬

cific airway conductance

Bouhuys,

1976).

(Bouhuys,

1969,

1970,

and Haynes

One problem with such measurements is that they are believed to

be an indication of constriction of larger airways,
cially mild bronchosapasm)
ripheral airways.

may be a disorder of

As obstruction becomes

while asthma (espe¬

the smaller,

more pe¬

more severe in asthma,

how¬

ever, larger airways are more likely to become involved.
Despite the variability

in the earlier studies

er's work,

the

early studies described a rather

EIB (Jones,

1962, McNeill, 1966,

Godfrey,

1975,

following Herxheimconsistent course for
and Anderson,

1975).

McFadden and Ingram describe EIB stating:
The pattern of response to exercise is characteristic.
Moder¬
ate bronchodilation occurs
during the early part of exercise
and gives way to bronchoconstriction after work ceases.
The
airway obstruction is progressive, generally reaching its peak
5-10 min after exercise has stopped.
The obstruction then be¬
gins to abate.
Spontaneous recovery is usual,
tending to be
complete within 30-90 min,
depending upon the severity of
bronchospasm
(McFadden, 1983).
Thus, by the early 1970's EIB was a better characterized phenomenon.
addition,

In

the development of more sensitive ways to measure EIB and new

pharmacological agents were inspiring further studies addressing the pa¬
thogenesis of EIB.

II
THE TRIGGER OF EIB: RESPIRATORY HEAT LOSS

A major question

that interested investigators was

exercise specifically triggers EIB.

what feature of

Three major factors were suspected:

(1) hypocapnia from the hyperventilation of exercise,

(2) stimulation of

airway mechanoreceptors by hyperventilation, and (3) lactic acid release
from skeletal muscle during exercise.
porting evidence,

but

Each of these hypotheses had sup¬

conclusive studies awaited the

partial rebreathing technique

development of a

that allowed the study of

the effects of

hypocapnia, hyperpnea, and acidosis independently of one another (McFadden, 1977a).
Support for hypocapnia
on three lines

as a cause of

of evidence.

that asthmatics had a decrease

First,

bronchoconstriction was based

Hafez

and Crompton

in FEV1 after voluntary hyperventilation

that did not occur in bronchitics or control subjects.
FEV1 did not occur,
induced

while the

1968).

Second,

however,

demonstrated

This decrease in

in the subjects when hyperventilation was

subjects were

breathing 5%

carbon dioxide

(Hafez,

Ferguson found the arterial partial pressure of carbon

dioxide to be lower after exercise in

patients with EIB than in healthy

controls or even in patients with diffuse lung disease.

As in the first

study cited above, Ferguson's asthmatics had a post-exercise decrease in
FEV1 that

was blocked

by the addition

case) to the inspired air (Ferguson,

5

of carbon

1969).

dioxide (3%

Similarly,

in this

Fisher showed

6
that the administration

of 6-8% carbon dioxide

pasm induced by running (Fisher,

1970).

could prevent bronchos-

Of note, this EIB was not pre¬

vented by inhalation of atropine sulfate.
Several other

researchers,

different from those

however,

were obtaining

claiming that hypocapnia was the

Chan-Yeung demonstrated a correlation between
lation and the

post-exercise decline in FEV1,

results quite

trigger for EIB.

the degree of hyperventi¬
but found

a greater de¬

cline in FEV1 when subjects inspired 5.6% carbon dioxide during exercise
(Chan-Yeung,

1971).

Stanescu and Teculescu reported the case of a pa¬

tient with EIB whose

attacks were not prevented by inhaling

6.5% carbon dioxide (Stanescu, 1970).
groups (Simonsson,
patients who

1972a, Bar-Or,

These workers,

as well as other

1977, and Sheppard, 1982),

experienced less bronchoconstriction from

EIB resulted

from hyperventilation

found some

exercise,

air, or hyperventilation when pre-treated with atropine.
postulated that

as much as

cold

These authors

stimulating airway

receptors acting via a vagal reflex.
The use of
to

a partial rebreathing technique by

the conclusion

cause of

EIB.

that hypocapnia

This technique

rest breathing to simulate the

from hyperventilation

involved having subjects

dioxide tensions.

produced by hypocapnia or hyperventilation,
were quite small

by actual exercise (McFadden,

was not

the

physically at

minute ventilations reached in exercise,

while varying the end-tidal carbon

carbon dioxide levels,

McFadden's group led

1977a).

count for the initiation of EIB.

The bronchospasm

even with higher end-tidal

in comparison to that produced

Hypocapnia did not adequately ac¬

7
Another factor proposed by other
lus in EIB was

the release of lactic acid resulting

metabolism of exercising muscles.
er,

researchers as the inciting stimu¬

1970, and Vassalo,

Several studies (Seaton,

1969, Fish¬

1972) documented either a metabolic acidosis,

creased lactate, or both in subjects with EIB.
that patients exercising
exercising on

from the anaerobic

However, Silverman found

on a treadmill had more severe

a bicycle,

despite

the subjects having

blood lactate levels during bicycling.

Furthermore,

for bronchoconstriction in exercise.
volved measuring blood pH during

EIB than those
higher arterial

the arterial blood

pH was similar in the two forms of exercise (Silverman,
performed a study that convincingly

in¬

1972a).

Strauss

eliminated acidosis as the stimulus
The first

exercise.

part of this study in¬

The exercise challenge was

then repeated while infusing enough sodium bicarbonate into each subject
to prevent acidemia.

All of the subjects experienced EIB

severity on both the control and
this study involved
and lactate

bicarbonate days.

to precipitate

"threshold" dose of lactate was then
None of the subjects developed
idemia (Strauss,

The second part of

the determination of the lowest

level needed

1977a).

EIB in

of the same

amount of exercise

each subject.

This

infused into each subject at rest.

bronchoconstriction with this lactic ac¬

This effectively ruled out a role for lactic

acidemia as the trigger for EIB.
The key to the
den's group once
by Salter in 1864:

initiation of EIB was elucidated by
they returned to examine the

Deal and McFad-

very phenomenon observed

the effect of temperature on EIB.

In their initial

study on the effects of temperature they found that cold air had a rath¬
er small,

but statistically significant,

bronchoconstrictive effect on

8
resting asthmatic subjects.
caused a

However,

inspiring cold air during exercise

markedly enhanced bronchospastic response.

Specific conduc¬

tance decreasd 85% and FEV1 decreased 100% more than when subjects exer¬
cised while breathing ambient air (Strauss,
this group and others confirmed that
not only by the

temperature,

air (Bar-Or, 1977, Chen,
1979b).
pasm,

1977b).

Further studies by

the severity of EIB was determined

but also by the humidity

1977, Strauss,

1978,

Deal,

of the inspired
1979a,

and Deal,

Cooling and drying the inspired air caused increased bronchoswhile heating and humidifying inspired air decreases the response

to exercise.

McFadden summarizes how this occurs in the airways as fol¬

lows :
With exercise,
as ventilation increases to meet metabolic de¬
mands,
a large volume of air at ambient conditions is brought
into the thorax where it must be heated to 37 degrees Centi¬
grade and fully saturated with water vapor before it reaches
the
alveoli.
This
requires evaporation of water and the
transfer of heat from the mucosal
surfaces of the airways.
The colder the air, the drier it is,
and so more heat and wa¬
ter are transferred,
and so
the more mucosal
temperature
drops.
The degree of obstruction that develops
is directly
related to the total amount of heat transferred and so to the
degree of cooling that develops....
(McFadden, 1981)
This relationship can be quantified and
tory heat

loss varies directly

versely with

(Deal,

1979b).

with the

1979b).

with the

the temperature and humidity

1979a and Deal,
directly

it has been shown that respira¬
level of ventilation
of the inspired

This respiratory heat loss,

percent

drop in

FEV1

air

and in¬
(Deal,

in turn, correlates

post-exercise in

asthmatics

Ill
BEYOND THE TRIGGER: THE AUTONOMIC NERVOUS SYSTEM

While the theory
explained the

of respiratory heat loss seems

initiation of

EIB,

to have adequately

much controversy

remains as

to the

mechanism by which airway cooling leads to bronchoconstriction.
There are two areas of speculation on

the effects of cooling of the

airway that are worth mentioning briefly.

Some preliminary in vitro an¬

imal studies "have shown that cooling
constriction,

as

(McFadden, 1981)

well as diminished responsiveness
McFadden notes,

for or against this in humans,
el is wrong for
for EIB.

of airway smooth muscle can cause

however,

to isoproterenol."

that while there is no data

the time course seen in the in vitro mod¬

a direct constrictor effect to be

the sole explanation

He points out that as soon as exercise ends,

to rewarm and return to their

the airways begin

baseline temperature within five minutes,

while bronchospasm gets progressively worse

over this same time period.

Therefore, something else must be sustaining the obstruction.
Another interesting speculation
the possibility of
ceptors.

that is based on

an interconversion of alpha and

animal studies is
beta adrenergic re¬

The idea here is that cooling of tissues leads to a conversion

of beta receptors to alpha receptors, so that stimulation of smooth mus¬
cle

with circulating

catecholamines would

than relaxation (Haynes,

1976, Kunos,

1980,

produce contraction
and McFadden,

rather

1982).

As

with the direct cooling theory discussed above, there is no evidence for

9

10
this phenomenon in humans and there is still the problem with accounting
for the time course of the

obstruction in EIB.

Furthermore,

the evi¬

dence for the interconversion theory comes from submammalian species and
is controversial in its own right (Benfey,
The role of
sial.

1980).

the autonomic nervous system in

EIB remains controver¬

The adrenergic system has been implicated in asthma in many dif¬

ferent ways.

Beta adrenergic

bronchodilatation (believed to

stimulation has

been shown

be through activation of

lase and increasing cAMP levels in smooth muscle cells)
IgE dependent release
Webb-Johnson,
to be

of mediators from lung tissue

1977).

1976).

adenylate cyc¬
and to suppress

(Orange,

1971 and

Much evidence has accumulated showing asthmatics

hyporesponsive to

Szentivanyi,

to produce

beta adrenergic

stimulation (Reed,

1974 and

Some workers have found an exaggerated rise in cir¬

culating catecholamines in asthmatics during exercise, which they postu¬
late is an attempt to overcome receptor hyposensitivity (Griffiths,
and Beil, 1977).

Others have found no differences in catecholamine lev¬

els between asthmatics and healthy
santhopoulos,
mine

1978).

controls (Anderson,

1976 and Chrys-

One group has even reported a decreased catechola¬

response following

(Barnes,

1972

exercise

in asthmatics

using

a newer

assay

1981b).

Studies using beta blockers in EIB

have raised the possibility of a

role for alpha adrenergic involvement in EIB.
gic hyperresponsiveness

has been suggested

A role for alpha adrener¬
by four lines

(1) increased EIB after beta blockade (Grieco,
bronchoconstriction

on

administration

blockade (Simonsson,

1972b, Prime,

1972,

of

of evidence:

1971 and Jones 1972),

catecholamines

and Patel,

1973),

after
(3)

(2)
beta

reduced

11
EIB in some patients after alpha blockade (Bianco,
and Biel,

1978), and (4)

1974,

Patel,

1976,

greater response to alpha stimulation in asth¬

matics as measured by vascular and pupillary response (Henderson,
However,

1979).

there are other studies showing that asthmatics may respond to

alpha blockade with bronchoconstriction rather than dilatation (Spector,
1979 and Shiner,

1983).

Thus,

no consistent picture

emerges for an

adrenergic role.
The possible role of the parasympathetic
tem in

EIB was already mentioned

branch of the nervous sys¬

since the mechanoreceptor

theory for

EIB was postulated to involve a vagal reflex.
While heat flux, and not mechanical stimulation,
mechanism for the initiation of EIB,
reflex may still

it has been suggested that a vagal

mediate EIB if there are

receptors in the airways (Enright,

is now the accepted

temperature sensitive neural

1979 and McNally,

1979).

Studies

supporting this theory have found decreased EIB after the application of
a topical anesthetic

to the posterior pharynx and

authors postulate that
flex.

the topical anesthesia interrupts

These studies, however,

duplicated (Fanta, 1980 and Griffin,

agents)

the

initial results were not

1982).

the role of vagal reflexes

have shown that

atropine (or

has arisen because

other anticholinergic

can attenuate bronchospasm produced by exercise,

tion, or cold air breathing.

the vagal re¬

When subsequent studies were done

with appropriately controlled conditions,

some investigators

The

did not adequately control for ventila¬

tion rate or inspired air conditions.

Further confusion on

upper airways.

hyperventila¬

This was found in some asthmatics, but not

in others (Stanescu, 1970, Crompton,

1968,

McNeill,

1966,

Simonsson,

12
1972a, Breslin,

1980b, Deal,

Thomson, 1978).
to have

an influence

on the

1980b).

results have been:

(1)

effectiveness of

Alternative explanations for these variable

1978, Rasmussen,

1978,

anticholinergics influence respiratory
and (3)

1972 and

Kaliner,

asthmatic subjects'

are known
1977)

determined.

1973).

role in EIB,

mediator release

is a positive

of EIB,
(Kaliner,

correlation between

Thus,

the autonomic nervous system

though how important a role

is yet to be

Current consensus suggests that the autonomic nervous sys¬

tem alone does not account for the
EIB.

cholinergic mediation

to enhance

and there

1982).

sensitivity to methacholine challenge and the sever¬

ity of their EIB (Kiviloog,
may well play a

1980),

the possibility that inadequate doses of atropine

above arguments against

cholinergic agonists

and McFadden,

heat loss themselves (Bres¬

may have been used in some studies (Sheppard,
Despite the

anticholinergics (Deal,

the mechanism for the obstruction has more than

one determinant (Thomson,

lin, 1980b),

1979, and

Different inspired air conditions have also been found

1978 and Breslin,

(2)

1978, McFadden, 1977b, Rasmussen,

obstruction produced by heat loss in

IV
BEYOND THE TRIGGER: MEDIATORS

The other major area of research
obstruction in EIB has been the role

concerning the mechanism of airway
of chemical mediators.

field that has seen a tremendous amount
years.

This is a

of activity in the past fifteen

Many mediators have only recently been identified in their pure

biochemical form,

while

pletely characterized.

still others have yet to be
Much

isolated and com¬

of the work on mediators in

EIB has been

suggested by the findings involving mediators in allergic asthma.
Before reviewing the

literature on specific mediators,

it will be

helpful to examine the evidence for and against mediators in EIB in gen¬
eral.

In a

study of considerable interest in 1977,

demonstrated mediator release

from sensitized mast cells

skin of patients with cold urticaria (Soter,
thors have postulated

Soter and Austen

1977).

in the cooled

By analogy some au¬

that a similar phenomenon occurs

with cooling of

the airways in EIB.
The drug

disodium cromoglycate

(DSCG)

has

been shown

to inhibit

bronchoconstriction due to exercise and isocapnic hyperventilation,
only if given before these challenges (Silverman, 1972b,
and Breslin,
tone.

1980a).

1976,

This drug does not usually affect baseline airway

As the main mode of action of DSCG is believed to be the stabili¬

zation of mast cell membranes,
EIB by

Haynes,

but

inhibiting the

this

work would explain DSCG preventing

release of mediators

13

stored within

mast cells.

14
Other drugs that also prevent mast cell degranulation , such as diethylcarbamazine pamoate
1976),

(Sly,

1974a),

and calcium channel blockers

beta adrenergic
(Cerrina,

agonists (Godfrey,

1981 and Patel,

1981),

have also prevented EIB in some trials.
The last

line of indirect evidence

supporting a role

for mediator

release in EIB comes from the existence of a "refractory period" in EIB.
If exercise challenges are repeated at short intervals,
tic response decreases (McNeill,
This has

been interpreted by

1966, James,

the bronchospas-

1976, and Edmunds,

some as evidence

1978).

for the depletion

of a

stored mediator that must be regenerated over a period of time.
Nevertheless,
EIB.

DSCG

some work has cast doubt

has been shown to

decrease the bronchospastic

cold air in normal subjects and to

1981).

1981,

Harries,

1981,

in
and

Since neither of these situations are believed to in¬

volve mediator release,

DSCG may well work by other mechanisms.

the role of DSCG in EIB may
diator release.

response to

sulfur dioxide (an irritant gas)

both asthmatics and normal controls (Fanta,
Sheppard,

on the role of mediators in

Thus,

involve an effect other than decreasing me¬

Just the fact that normal individuals, who do not have

sensitized mast cells,

can be made to develop obstruction with exercise

and other similar stimuli is cited as evidence against mediator involve¬
ment (at least mediators from mast cells)

(McFadden,

This controversy over mediators extends
cific mediators.
lease of

histamine

into the literature on spe¬

Histamine was examined first because of the known re¬

histamine during mast

asthma (Valentine,

1983).

1976).

turnover during

cell degranulation in

allergen induced

While one earlier paper showed no increase in
exercise

in

subjects with

EIB

(Granerus,
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1971),

other workers have demonstrated

venous plasma histamine
in EIB (Ferris,
However,

increases in either arterial or

levels that are correlated

1978, Barnes,

1981a, Anderson,

with decreased PFTs

1981,

and Lee,

1982a).

Deal and McFadden's group found no increase in arterial hista¬

mine levels following challenge by

isocapnic hyperventilation with cold

air (a stimulus equivalent to exercise)
Interestingly,

(Deal,

1980).

in the same above mentioned study.

Deal and McFadden

failed to find an increase in neutrophil chemotactic activity (NCA) when
subjects performed isocapnic hyperventilation with cold air.
this finding to
tors are

support their conclusion that mast

not involved in EIB.

kins (Atkins,

1977).

ciated with the
(Wasserman,
of asthmatic

It is the same mediator that was found to be asso¬

study,

subjects after exercise on

similar to
but used

urticaria mentioned earlier

NCA has since been shown to be present in the serum

partially purified (Lee,
is quite

high molecular

in antigen induced asthma by At¬

phenomenon of cold induced

1977).

cell derived media¬

NCA is a heat-stable,

weight factor that was first described

They took

1982b).

a treadmill and has

even been

The time course for the release of NCA

that of histamine

release.

a treadmill challenge looking for

Lee

repeated Deal's

NCA release.

This

time the exercise was performed once while inspiring warm, humid air and
on a second occasion with subjects breathing cold, dry air (Lee,
This study

showed that EIB

cold exercise challenge,
ventilation with
strating that

and NCA

both appeared together

while neither

warm air.

These

during the

were produced during the hyper¬

results were interpreted

respiratory heat exchange

additional mechanism)

1983).

together cause mast

and exercise (by

as demon¬

some unknown

cell mediator release.

Lee
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further postulated that isocapnic

hyperventilation might cause mediator

release, but at levels that are only detectable with the addition of ex¬
ercise.

Lee reviewed some of the literature already discussed above on

vagal reflexes and suggested that different sites and mechanisms of air¬
way obstruction may exist in
that supports

different subjects.

this multiplicity of

One additional study

mechanisms involved

exercising pa¬

tients repeatedly at short intervals until they no longer responded with
EIB.

These subjects were then challenged with an allergen known to pro¬

duce bronchospasm in the subjects.
study remained responsive
(Weiler-Ravell,

1981).

ble to respond to

Six

of the twelve subjects in this

to the allergen while the other

six were not

One would expect all of the subjects to be una¬

the allergen if the exercise had

tors necessary to produce bronchospasm.

Thus,

depleted the media¬

the subjects in Weiler-

Ravell' s study may represent two subgroups of of people with EIB:
with

mediator-dependent EIB

and those

with EIB

produced via

those
another

mechanism.
Slow reacting substance of anaphylaxis (SRS-A)
mediator of allergen (Ig E)

is another important

dependent bronchoconstriction that has been

investigated extensively in recent years (Orange, 1969).

In contrast to

histamine and NCA, SRS-A is extractable from lung cells only after immu¬
nological challenge
(Brocklehurst, 1960).
release of SRS-A

and,

thus,

is

not a preformed,

While the need for an immunological stimulus for

seems to speak against its involvement

are a few reasons for briefly mentioning SRS-A here.
lators of EIB

stored mediator

were first discovered in work on

and there simply has not been much work

in EIB,

there

First, many modu¬

allergen induced asthma

to date on the role of SRS-A in
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EIB.

Second,

in EIB.

there are two studies that suggest that SRS-A is involved

The drug diethylcarbamazine citrate,

inhibit SRS-A release in rats (Orange,
of twenty asthmatic subjects when
1974b).

Lastly,

SRS-A

given before exercise challenge (Sly,
consisting of three

LTC4, LTD4, and LTE4.

These leukotrienes

arachidonic acid and are closely related

teract with prostaglandins (Murphy,
rey,

prevented EIB in fifteen

has been characterized as

distinct leukotrienes (LTs):
are derivatives of

1968),

which has been shown to

1980, and Samuelsson,
Leukotrienes are

1979, Morris,

to and in¬

1980, Lewis,

1980, Co¬

1982).

released by human

with allergen (Orange, 1973 and Austen,
very potent spasmogens on isolated

lung fragments
1974)

when challenged

and have been shown to be

human bronchi (Dahlen,

1980).

LTC

and LTD are also potent constrictors of human airways in vivo (Holroyde,
1981 and Weiss,

1982).

How leukotrienes

subject of much

current research,

produce these effects is the

with one area of

interaction of leukotrienes and prostaglandins.
of compounds are

After all, both classes

derived from arachidonic acid with

ygenase and cyclooxygenase being the first

interest being the

the enzymes lipox¬

step in the production path¬

way for leukotrienes and prostaglandins, respectively.
studies have suggested that in some
the production of thromboxane,

a

In vitro animal

situations leukotrienes may act via
product of the cyclooxygenase pathway

(Piper, 1981, Schianterellli, 1981,

and Folco,

1981).

Interestingly,

studies using inhibitors of various steps in arachidonic acid metabolism
seem to indicate

that LTD4 (at least)

has both

a thromboxane mediated

and a direct bronchoconstrictive effect (Muccitelli,
1984).

Further

elucidation of

the actions

1983 and Weichman,

and mechanisms

of leuko-

trienes will be important for

understanding allergen induced asthma and

possibly EIB.

.

V
PROSTAGLANDINS

Prostaglandins are the products of the cyclooxygenase pathway of arachidonic acid metabolism.

Earlier work on prostaglandins in asthma was

initially centered on prostaglandins E2 and F2'< (PGE2 and PGF2<*.).
are formed in

high concentrations in the

lung relative to the

Both
rest of

the body (Karim, 1967), with lung parenchyma having much more PGF2« than
PGE2,

while isolated bronchi have been

PGE2 (Shaw,

1975).

Several lines of evidence exist to suggest the in¬

volvement of PGE2 and PGF2

in the regulation of airway tone.

bronchodilator in vitro (Sweatman,
(Smith,

found to have a predominance of

1968 and Gardiner, 1975)

PGE2 is a
and in vivo

1973 and Smith, 1975a), while PGF2°< is a bronchoconstrictor both

in vitro (Sweatman, 1968 and Gardiner,

1975) and in vivo (Smith,

Mathe,

1977).

1973, Mathe, 1975, and Newball,

mediators,

PGF2*< is a far

1975a,

Like many other potential

more potent bronchoconstrictor in asthmatics

than in normal subjects (Newball,

1980).

The effects of these prosta¬

glandins are not altered by antihistamines or anticholinergics,

suggest¬

ing that the effects are independent of other mediators and the autonom¬
ic nervous system (Sweatman,
that PGE2

and PGF2®< may act

metabolism (Shaw,

1975)

contraction (Carsten,
ies have implicated

1968 and Shaw, 1975).

Some studies suggest

either through changing

or via an

cyclic nucleotide

effect on calcium and smooth muscle

1972, Higgins,

1972, and Shaw,

an interaction with histamine,

19

1975).

Other stud¬

with PGs affecting

20
either the release of or the sensitivity to histamine (Tauber,
Walters,

1973 and

1983).

As with leukotrienes,
gic asthma by

prostaglandins have been implicated in aller¬

studies that have shown

the release of PGF2°c

lung fragments that had been passively

from human

sensitized and then subjected to

antigen challenge (Piper, 1973).

The principal metabolite of PGF2* has

also been shown to be elevated in

the plasma of subjects after an anti¬

gen inhalation challenge (Green, 1974).
Prostaglandin D2 (PGD2) and thromboxane A2 (TXA2)
clooxygenase products that have been

investigated recently in a fashion

similar to previous work on PGE2 and PGF2** .
released by sensitized lung fragments in
tigen (Schulman, 1980a and Schulman,

1977),

1980b).

In fact, PGD2 and TXA2 are
in vitro (Hamberg,

Furthermore, PGD2 is released in larger quantities

than PGF2°< in allergen challenged lung

tissue as well (Schulman,

1981,

1982, and Peters, 1983).

From the literature cited above it
involved at least in

allergic asthma,

tions remaining to be answered.

One

is clear that prostaglandins are
though there are a

lot of ques¬

interesting dilemna concerns non¬

steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin.
drugs are inhibitors of cyclooxygenase and,
din synthesis (Vane,

1971 and Flower,

thus,

1972).

choconstrictive prostaglandins is responsible
EIB,

1975 and

and PGD2 is more potent than PGF2«< when inhaled by hu¬

mans (Hardy, 1984).

Lewis,

These substances are also

vitro when challenged with an¬

more potent bronchoconstrictors than PGF2°<.
Svensson,

are two other cy¬

then one

These

they block prostaglan¬

If the generation of bronfor airway obstruction in

might expect NSAIDs to be bronchodilators,

or at least

21
prevent bronchospasm.

Indeed,

Szczeklik has reported a small group of

asthmatic subjects who do have bronchodilatation in response to aspirin,
another NSAID (Szczeklik,
there are

subjects who

(Szczeklik,

1975).

1983).

However,

develop asthma
Furthermore,

it is also well known that

attacks in

response to

there are studies

documenting that

NSAIDs have no effect (either increasing or decreasing)

on the broncho-

constriction elicited by allergen (Smith, 1975b and Fish,
cise (Rudolph,
line (Ogilvy,

1975, Smith,

1975c, and Schachter,

NSAIDs

1981),

1978b),

exer¬

or methacho-

1981) in asthmatic or normal subjects.

The literature on the role of prostaglandins
tensive,

due in

part to the difficulty of

vivo and

perhaps also

plasma levels to

to early negative

in EIB is not very ex¬

measuring prostaglandins in
studies.

Allegra

be significantly higher in asthmatics at

normal controls (Allegra,

1976).

He postulated that this

compensatory mechanism to raise cAMP in
ergic hyposensitivity.

found PGE

rest than in
might be a

asthmatics who have beta adren¬

(This is similar to the argument discussed ear¬

lier that was put forth by those who found baseline catecholamine levels
elevated in asthmatics.)

Allegra1s group, however,

nificant difference between pre- and

did not find a sig¬

post-exercise plasma levels of PGE

and PGF2« in asthmatic subjects exercised on a treadmill (Field,

1976).

Another group

in the

plasma level
1976).

This,

of workers actually found
of the

major metabolite

of course,

were caused by an

a significant decrease
of PGF2°<

is contrary to

increase in PGF2‘<.

during EIB

what one would expect if EIB

This group

that PGF2°< does not play a significant role in EIB.
ity suggested by Allegra1s group is

(Anderson,

of workers concluded
The other possibil¬

that systemic sampling from the pe-
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ripheral plasma

is just

quite significant

not sensitive

enough to

changes in local prostaglandin

the lung tissue (Field, 1976).

measure what

may be

concentrations within

It may be that even very sensitive pros¬

taglandin assays in the future will be unable to measure systemic chang¬
es if the entire

process is localized and rapid.

cially important

in light

PGF2<*,

even

of the finding

This

by Newball

in doses large enough to produce

issue is espe¬
that intravenous

uterine contractions and

watery diarrhea in some subjects, produced much less bronchoconstriction
than smaller doses of inhaled PGF2<< (Newball, 1976).

It should be noted

that this difficulty is present to some extent where any attempt is made
to measure any proposed chemical mediator in a clinical trial.
As mentioned earlier,
inhibitors on
EIB.

EIB speak

studies showing no effect
against a primary

role for

of cyclooxygenase
prostaglandins in

However, there is one study by Souza and Silverman that looked at

the effects of a single oral dose (25 mg) of indomethacin on EIB.

They

found that five of the twelve subjects were at least partially protected
against EIB by the indomethacin (Souza, 1981).
however,

It must be pointed out,

that this study used PEFR as an indicator of EIB,

the three
•indicators

negative studies alluded to
FEV1 and MEF40%(P)

inhalation of PGF2

These researchers used

These studies

1978b).

does not protect against bronchos(Patel,

this data to conclude

tive action of PGF2*< is due to

more sensitive

(Smith, 1975a and Schachter,

Two studies have shown that DSCG
pasm induced by

earlier used the

while two of

1975

and Newball,

1977).

that the bronchoconstric-

a direct effect on airway smooth muscle.

also present indirect evidence

against the role

of PGF2°c

in EIB since DSCG does protect against EIB in many subjects, yet it does
not prevent bronchospasm due to PGF2<* administration.

VI
ASCORBIC ACID

The possibility that
first raised

ascorbic acid might be involved

in the early nineteenth

scribed symptoms of asthma in
1803).

in asthma was

century by Reisseissen,

who de¬

patients with severe scurvy (Reisseissen,

This observation suggests the

following question:

if ascorbic

acid deficiency can produce asthma, can ascorbic acid prevent or amelio¬
rate asthma in non-scorbutic asthmatics?
While this

issue does not compare

question of the

effect of ascorbic acid

there is controversy
question of

the protective effect of

Hunt in 1938.

from a daily oral
number and

He

was unable to demonstrate

episodes in

The

has been

any benefit

as measured by the
asthmatic subjects.

the intramuscular or intravenous injec¬

acid (500-800 mg doses)

given

during acute asthmatic

1938).

Another simple clinical
ria.

on asthma.

ascorbic acid in asthma

dose of 100 mg of ascorbic acid,

Hunt also found no benefit from

episodes (Hunt,

common cold,

One of the first therapeutic trials was

severity of bronchospastic

tion of ascorbic

surrounding the

on cancer or the

over the effect of ascorbic acid

raised in many different ways.
performed by

with the uproar

trial was performed more

recently in Nige¬

41 asthmatics, all of whom had increased numbers of attacks during

the country's rainy season, were studied.

These patients had exacerba¬

tions of their asthma precipitated by respiratory infections (recognized

23
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by the report of sore throat and dry cough).
one gram of ascorbic

22 of these subjects took

acid daily for 14 weeks,

while

jects took a placebo for the same length of time.
subjects receiving

ascorbic acid had

the other 19 sub¬

During this trial the

fewer asthmatic episodes

less severe attacks than those in the placebo group.
ments of plasma

ascorbic acid levels confirmed

and far

Interval measure¬

a significantly greater

level in the subjects assigned to the ascorbic acid group (Anah,
While this

study did

not involve

a crossover

of treatment

1980).

regimens,

there was a marked increase in the number and severity of asthma attacks
for the ascorbic acid subjects once the trial was terminated.
ly,

there

are many

problems with this

study,

including

Obvious¬
reliance on

self-reporting of attacks and their severity without any objective meas¬
urement of lung function,

but the most important difficulty seems to be

the selection of a group of
respiratory infections.
ficial effect

patients whose attacks were precipitated by

This study claims to have demonstrated a bene¬

of ascorbic acid in

measuring a protective

asthma,

but may actually

effect of ascorbic acid

have been

against respiratory in¬

fections .
Other more rigorous

studies have looked at the

effects of ascorbic

acid against bronchoconstriction produced by means other than respirato¬
ry infections.
mine induced

Bouhuys initially demonstrated
bronchoconstriction in

oral doses of 500 mg of ascorbic

an inhibition of hista¬

healthy subjects
1973).

Workers in the

same lab later

were unable to document this protective

effect in asth¬

matic subjects

treated for three days

(Kreissman, 1977).

acid (Zuskin,

following single

with 500 mg ascorbic

acid daily

A study by Cockroft et al also failed to show a pro-
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tective effect of one gram doses

of ascorbic acid against histamine in¬

duced bronchospasm in asthmatics (Cockroft,
of asthma

induced by textile

1977).

Similarly,

dust inhalation have

ition of bronchospasm by ascorbic acid (Valic,

studies

demonstrated inhib¬

1973 and Zuskin,

1977),

while other investigators using ragweed as

the antigen found no benefit

from the use

1977

Single oral

of ascorbic acid (Kordansky,
doses of one gram

and Kordansky,

of ascorbic acid

decreased methacholine

induced bronchospasm in both healthy subjects (Ogilvy,
matics (Mohsenin, 1983).
gram of

1981)

and asth¬

One study of ascorbic acid in EIB utilized one

ascorbic acid given intravenously

2.5 hours prior

and then measured the response to exercise
investigation ten subjects were studied:
had an increase in EIB,

and six

to exercise

by PEFR and MMEFR.

In this

two had a decrease in EIB,

two

subjects had no change in the severity

of EIB after infusion of ascorbic acid (Anderson,
tant to note, however,

1979).

1983).

It is impor¬

that one of the parameters used to determine the

pulmonary response to exercise was the PEFR.

As mentioned earler,

this

measurement is effort dependent and may

not be reliable.

Since Ander¬

son's paper did not show specific data,

it is possible that reliance on

this parameter may have led to spurious conclusions.
Finally,

one

other study on ascorbic

acid and EIB,

performed by

Schachter and Schlesinger, did demonstrate the beneficial effects of as¬
corbic acid (Schlesinger,
volved pre-treatment

1980 and Schachter,

with 500 mg of

minutes prior to exercise challenge.
a history

of mild

MEF40% or MEF40%(P)

1982).

ascorbic acid or a

Their study in¬
placebo ninety

The subjects in the study all had

asthma and documented

EIB (at least

a 20%

drop in

on an exercise challenge on a prior screening day).
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PFTs were measured at the following times:
after exercise,
tion of a

five minutes after exercise,

bronchodilator.

was

immediately

and after the administra¬

FVC and FEV1 were the

consistently demonstrated the
though MEF40%(P)

before exercise,

parameters that most

protective effect of ascorbic

the most sensitive indicator

acid,

al¬

of bronchoconsfric¬

tion.
In vivo

animal studies and

the anti-bronchospastic actions

in vitro experiments

have demonstrated

of ascorbic acid and have

been used to

suggest the mechanism, or mechanisms, by which this protective effect is
attained.

Early work centered on the

interaction of ascorbic acid and

histamine, since some studies showed that ascorbic acid protects against
anaphylaxis induced by antigen or histamine in various animals (Guirgis,
1965, and Dawson,
guinea pigs

1965,

1966,

and 1967).

on an ascorbic acid

Chatterjee et al found that

free diet developed

markedly elevated

histamine levels in plasma and other tissues (Chatterjee,
ther work by this group suggested that

1978).

the effect of ascorbic acid that

well evaluated are reviewed by Schlesinger (Schlesinger,
include an effect

Fur¬

ascorbic acid had this effect by

influencing the metabolism of histamine (Subramanian,
possible mechanisms for

1975).

on cyclic nucleotide metabolism,

Some other

have not been
1980).

These

smooth muscle cell

calcium flux, and a direct effect on airway smooth muscle related to the
action of ascorbic acid as an antioxidant.
The area
been the
glandins.

that has

produced exciting research

studies of the interaction

in recent

between ascorbic acid

years has
and prosta¬

Puglisi et al have found an increased production of PGE2 (the

brochodilating PG)

in guinea pig

tracheal tissue treated with ascorbic
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acid (Puglisi,

1977).

In a complementary study,

this group also demon¬

strated that more PGF2°<. (the bronchoconstricting PG)
duced by

tracheal tissue from

than PGE2 was pro¬

scorbutic guinea pigs

(Puglisi,

1976).

They also discovered that in vivo treatment of guinea pigs with ascorbic
acid

antagonized the

(Puglisi, 1976).

bronchoconstriction induced

by intravenous

PGF2°*

This work led to the attractive hypothesis that ascor¬

bic acid alters PG metabolism in favor of PGE2 production over PGF2<* re¬
sulting in a net bronchodilating
the protection by

effect.

Two clinical studies showing

ascorbic acid against methacholine

induced bronchos-

pasm support this hypothesis, since the administration of the PG synthe¬
sis inhibitor
acid (Ogilvy,

indomethacin blocked
1981 and Mohsenin,

the beneficial

1983).

had no effect on methacholine induced

action of

ascorbic

In these studies indomethacin

bronchospasm when given by itself

and neither ascorbic

acid nor indomethacin had a

significant effect on

resting airway tone.

Despite the lack of effect on resting tone, ascor¬

bic acid protected against methacholine, while ascorbic acid and indome¬
thacin given

together failed to

methacholine.

Thus,

attenuate the bronchospasm

induced by

these investigators postulated that ascorbic acid

protects against EIB by altering active prostaglandin metabolism so that
PGE2 production is predominant over PGF2°c.
Exactly how ascorbic acid alters

arachidonic acid and prostaglandin

metabolism is not known, but has been the subject of additional in vitro
studies.

It was mentioned earlier that ascorbic acid is an antioxidant

and,

thus,

alters the redox potential of any system to which it is add¬

ed.

Since it had been shown that reduced glutathione increases the pro¬

duction of PGE2 (Lands, 1971), some authors have suggested that ascorbic
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acid might increase PGE2 by maintaining glutathione in the reduced state
(Lands,

1971 and Puglisi,

1977).

However,

correlation between ascorbic acid and
(Leung,

1981 and Rothberg,

Hitchcock,

1983).

two studies have shown no

glutathione levels in lung tissue

One of these studies, by Rothberg and

did demonstrate that lung

microsomes from scorbutic animals

did produce more PGF2<< than microsomes from control animals when the ex¬
periment
1983).

was run

at

low

arachidonic acid

They suggest that,

oxidase enzymes (Danford,

as ascorbic

concentrations

(Rothberg,

acid does protect against some

1980), ascorbic acid may actually increase the

conversion of PGF2«c to PGE2.
The aim of the present study was to first confirm the existence of a
protective effect of ascorbic acid against

EIB.

Secondly,

it was ex¬

pected that if the protective effect was due to an alteration in prosta¬
glandin metabolism,

then the benefit of a dose of ascorbic acid would be

blocked by simultaneous adminstration of indomethacin.
lated that we would obtain results similar
that examined
bronchospasm.

ascorbic acid

Thus, we postu¬

to those seen in the studies

and indomethacin

in methacholine

induced

VII
METHODS

Asthmatic subjects were

recruited for this study

the university community for persons with mild asthma.
pitalized patients were not solicited because
more severe asthma.

Clinic and hos¬

of their tendency to have

All subjects had a history of asthma as defined by

the American Thoracic Society (Amer Thor Soc,
jects required corticosteroid therapy at the
subjects had asthma attacks at varying
quired hospitalization
formed consent as

by advertising in

1962).

time of the study.

frequencies,

for an attack.

None of the sub¬

no subject had re¬

All subjects gave

approved by the Yale

While

written in¬

University Human Investigations

Committee.
Each subject

completed a questionnaire detailing

toms, allergies, medications,
history of EIB.

medical illnesses,

(aspirin,

twenty-four hours prior to each test day.
refrain from ingestion of any food
of methylxanthines (coffee,

In order to be enrolled in
least a

screening exercise

and

20% reduction

ibuprofen,

etc.)

for

They were also instructed to

or beverage containing large amounts

tea, cocoa,

acid (citrus fruits, juices, etc.)

strate at

smoking history,

Subjects were instructed to take no asthma medications

or prostaglandin synthesis inhibitors

ing.

respiratory symp¬

soft drinks,

etc.)

or ascorbic

for twenty-four hours prior to test¬
this study each patient had to demon¬
from their

baseline MEF40%(P)

challenge that measured pulmonary
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on a

function response

30
to exercise without any test drugs.

A total of twelve subjects,

eight

male and four female, were entered into the study.
Pulmonary function

testing (PFTs)

volumes and flow rates derived from
volume curves (PEFV
the use of

forced expiratory

partial and maximal expiratory flow

and MEFV curves).

These curves

were generated by

a pneumotachograph integrator system and were

Gould X-Y recorder.
inspire to

consisted of

The PEFV curve

was created by having the subjects

approximately two-thirds of

forcefully to residual volume.

recorded on a

They

vital capacity and

then exhale

would then immediately inspire to

total lung capacity and exhale forcefully to residual volume once again,
thus generating

the MEFV

curve.

The

parameters obtained

from these

curves were the following:
1.

forced vital capacity (FVC),

2.

forced expiratory volume in one second (FEV1),

3.

peak expiratory flow rate (PEFR),

4.

flow rate after expiration of 50% of
spiration (Vmax50%),

5.

the volume of a maximal in¬

and

flow rates at 60% of baseline vital capacity below total lung ca¬
pacity on both MEFV and PEFV curves (MEF40% and MEF40%(P)).

Exercise

testing was

performed

in

an air-conditioned

laboratory

where the room temperature and humidity were relatively constant:
erature = 68 +/-

2° F

(range = 62-74°)

temp¬

and humidity = 59 +/- 7% (range =

50-71%).
Subjects exercised on a cycloergometer (Monark).
daling at a speed
each one minute

Subjects began pe¬

of 20 km/hr against a zero workload.
interval the subjects'

heart rate was

At the end of
measured with an
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electrocardiograph (Hewlett-Packard) and minute ventilation was measured
by directing

exhaled air through a

calibrated gas meter.

values were recorded the workload was
minute with subjects continuing
jects continued
either the heart

increased by 150 kilopond-meters/

to pedal at a rate of

this constant rate

Once these

20 km/hr.

Sub¬

against increasing

workloads until

rate exceeded 170 beats/minute or the

subject was too

fatigued to go on.
While exercising the subjects inspired through a mouthpiece connected
to an Otis-McKerrow valve.

A length of tubing connected the intake por¬

tion of the valve and mouthpiece to a column filled with calcium sulfate
granules (Drierite)

with the other end of

The outflow from the mouthpiece was
calibrated gas flow meter.

the column open to room air.

directed through more tubing to the

Subjects wore a nose clip so that they would

only be breathing the dried air through the mouth, bypassing the warming
and humidifying effects of the

nasopharynx.

This kind of experimental

apparatus produces an average partial pressure of water vapor of 3 mm of
Hg in the inspired air (Schachter,
As mentioned above,
cations and substances
twenty-four hours prior

1984).

subjects refrained from the use of asthma medi¬
containing methylxanthines or ascorbic
to each test day.

approximately the same time
avoid any diurnal variation.

Each subject

of day (+/- 2 hrs.)

on

acid for

was tested at

all trial days to

Whenever PFTs were measured, subjects per¬

formed the PEFV and MEFV maneuvers

three times,

vals between each pair of curves.

Thus, the values for any PFT parame¬

ter at a given

with one minute inter¬

time point were actually taken to be

values from the three sets of curves.

the average of the
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On the
Subjects

initial screening day a
then exercised

according

Three pairs of PEFV and MEFV curves

baseline set of PFTs
to

the protocol

was obtained.

described

above.

were then obtained at the following

times after completion of exercise:
1.

one minute,

2.

five minutes,

3.

fifteen minutes,

4.

thirty minutes, and

5.

sixty minutes.

After the

sixty minute

PFTs each

subject received

two metered

(0.65 mg each) of metaproterenol sulfate (Alupent) inhaler.
after the administration of this bronchodilator
measured (post-alupent curves).
20% reduction in MEF40%(P)

doses

Ten minutes

a final set of PFTs was

A subject had to experience at least a

from pre-exercise values at some point after

exercise to have sufficient EIB to go on to the rest of the study.
The remainder of
day a

the study consisted of four trial

pre-drug baseline set of

PFTs was obtained.

days.

On each

Subjects

then re¬

ceived two capsules that contained one of the following combinations:
1.

two placebos (lactose),

2.

one placebo plus 750 mg of ascorbic acid,

3.

one placebo plus 50 mg of indomethacin, or

4.

750 mg of ascorbic acid plus 50 mg of indomethacin.

These were given in a double-blind,

randomized,

that each subject received all four combinations,
ders.

crossover fashion such
just in different or¬

After ingestion of the two capsules there was a two hour waiting

period before beginning

the exercise challenge.

During

this two hour

33
period subjects were allowed to leave the laboratory, but were asked not
to exercise or eat.

After the waiting period the exercise challenge was

performed in identical

fashion to the screening day,

with PFTs before

exercise, after exercise, and after alupent.
All PFT

raw data points

were analyzed

after being converted

number reflecting the change from that day's baseline PFTs.

to a

The change

from baseline was expressed in two ways:
1.

The absolute change from baseline
a PFT

at a given

(simply the difference between

time and that PFT

prior to drug

ingestion on

that day) and
2.

The percentage change from baseline (calculated by taking the ab¬
solute difference,

dividing it by

the baseline value and multi¬

plying by 100).
In comparing

the effects

of one drug

changes on one day were compared to

combination to

another absolute

absolute changes on another day and

percentage changes from baseline were likewise compared.
culations for comparing ascorbic acid to placebo,
ally differences of differences.

reflect changes
values.
cant,

the cal¬

for example, are actu¬

All comparisons were made using paired

Student's t-tests (Snedecor and Cochran,
The percentage change

Thus,

1967).

from baseline was assumed

in the subjects because

to more accurately

of the wide range

of baseline

Clearly, a drop in MEF40%(P) of 0.3 1/sec is much more signifi¬
statistically and

MEF40%(P)
3.0 1/sec.

clinically,

for

a subject

with a

baseline

of 1.0 1/sec than for a subject with a baseline MEF40%(P)

of
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VIII
RESULTS

Tables 1 and 2 below give a
from the twelve subjects.

summary of the anthropometric data obtained
(Values are the mean +/- one standard devia¬

tion. )

TABLE 1
Anthropometric Data Summary

Subjects
12

Age (yrs.)
22.2+/- 2.6
(18-27)
Sex
4 Female
8 Male

Height (cm)
171.2+/-7.8
(157-180)
Race
10 White
1 Black
1 Oriental

34

Weight (kg)
62.1+/-22.4
(52-100)
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TABLE 2
History from questionnaire

Taking Asthma Medications

=

6

History of Chronic Bronchitis = 0
History of Smoking
History of EIB

=
=

(infrequent pipe)

12

worse EIB in cold weather =
worse EIB with URI

1

=

9
10

Frequency of Wheezing:
> once/week

=

6

- once/month

=

4

< once/month

=

2

Wheezing Exacerbated by:
Animals

=

9

Dusts

=

11

Pollens

=

10

Cigarette smoke

=

7

Cold weather

=

10

Exercise

=

12

Dust, Pollen, Mold

=

9

Hives

=

3

Eczema

=

4

Foods

=

4

Hayfever

=

10

History of Allergy :

L

j
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8.1

RESPONSE TO EXERCISE WITHOUT DRUGS
The initial screening day determined whether or not a subject quali¬

fied for the remainder of the study and also allowed for the characteri¬
zation of the subjects'
raw

data for

MEF40%(P).

response to exercise.

the response

to exercise

as

Tables 3 and 4 give the
measured by

the FEV1

and

All parameters showed a significant brochospastic effect at

five and fifteen minutes post-exercise (P <

.05), except for FVC,

showed a significant decrease only at the five minute point.
parameters, except FVC,

from baseline.

Again all

demonstrated a significant bronchodilatation in

response to the metaproterenol one hour after exercise (P <
values were significant

which

using both the absolute

.05).

These

and percentage changes
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TABLE 3
FEV1 Screening Day

Subject Base lmin 5rain 15min 30min 60min post-alupent
1

3.9

3.9

3.5

3.5

3.5

3.6

3.5

2

1.9

2.3

1.8

1.8

1.8

2.2

2.7

3

2.2

1.8

1.6

1.7

1.8

2.0

2.5

4

3.0

2.6

3.0

3.1

2.8

2.9

3.3

5

2.9

2.9

2.7

2.8

2.8

3.0

3.4

6

3.2

3.4

3.3

3.4

3.5

3.5

3.9

7

2.3

2.2

2.2

2.2

2.2

2.3

2.4

8

3.5

3.4

3.2

2.9

3.1

3.5

3.8

9

3.2

2.8

2.7

2.7

2.8

2.9

3.5

10

3.9

3.8

3.7

3.7

3.9

3.9

4.0

11

4.1

4.0

4.0

3.9

3.5

4.1

4.0

12

4.2

4.4

4.2

4.2

4.2

4.1

4.2

Mean

3.2

3.1

3.0

3.0

3.0

3.2

3.4

S.D.

0.8

0.8

0.8

0.8

0.8

0.8

0.6
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TABLE 4
MEF40%(P) Screening Day

Subject Base lmin 5min 15min 30min 60min post -alupent
1

2.6

2.5

2.0

2.5

2.8

3.9

3.9

2

0.9

1.1

0.7

0.8

1.0

1.1

2.0

3

1.4

0.7

0.4

0.3

0.5

0.4

1.6

4

1.6

0.9

0.8

1.0

1.3

2.1

3.5

5

1.5

1.4

1.0

1.0

1.4

1.2

2.1

6

2.1

1.6

2.0

2.3

2.9

2.9

4.6

7

0.8

0.6

0.5

0.5

0.7

0.8

1.3

8

2.1

2.0

1.4

1.2

1.6

2.1

2.9

9

2.7

0.9

0.8

1.0

1.5

1.8

3.6

10

2.8

1.9

2.0

2.1

2.3

2.6

3.8

11

2.9

2.1

2.2

2.5

2.9

3.7

3.6

12

4.1

4.0

3.2

3.1

3.7

3.3

5.2

Mean

2.1

1.6

1.4

1.5

1.9

2.2

3.2

S.D.

1.0

1.0

0.9

0.9

1.0

1.2

1.2

Of note,

these

EIB entirely.
to

While they did have

fifteen minutes

these subjects
exercise.

subjects did not demonstrate the

In fact,

bronchospasm that was worst at five

post-exercise which

did not

typical course of

improved over

experience bronchodilatation

both the PEFR and MEF40%(P)

the next

hour,

immediately after

were decreased at one

39
minute post-exercise (P < .05),

indicating brochospasm already at this

early point.
The twelve subjects

admitted to the drug portion of

selected on the basis of having a decrease in MEF40%(P)
from baseline at some point after

exercising.

ment in MEF40%(P) was 39% (+/- 19%),
maximal decrease in FEV1 was only 10%
of at least 10% had been used

the study were
of at least 20%

The mean maximal decre¬

with a range of 22-79%.
(+/- 8%).

The mean

If a decrease in FEV1

as the selection criterion,

only five of

the twelve subjects would have been enrolled in the drug trial.

8.2

RESPONSE TO EXERCISE WITH DRUGS

Tables 5 and 6

show the baseline PFTs for all

on the screening day.

subjects before exercise

This table also expresses the PFTs

the predicted values for an individual of the same height,

in terms of
weight,

and

race.
Tables 7 and 8 then compare
(pre-exercise)

the FEV1 and MEF40%(P)

on all of the study

days.

baseline values

This data demonstrates that

the subjects were starting in essentially the same state each day before
taking any of the

drug combinations (P >

tween any two days).

.05 for

comparing any PFT be¬
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TABLE 5
Baseline Pulmonary Function Testing

1
PEFR

FEV1

FVC

1/sec

%pred

1/sec

%pred

101

3.9

112

9.2

132

3.3

95

1.9

62

3.5

61

3

3.3

95

2.2

74

4.9

88

i

4

4.0

114

3.0

100

5.6

100

1

5

5.1

107

2.9

72

5.7

73

1

6

4.4

93

3.2

82

6.8

89

7

3.4

104

2.3

81

4.8

87

1

8

4.8

101

3.5

88

6.9

88

i

9

4.5

80

3.2

71

5.6

68

10

4.9

113

3.9

108

8.6

115

11

5.0

111

4.1

110

6.8

91

12

4.6

114

4.2

126

9.2

134

|

Mean

4.3

102

3.2

90

6.5

94

|

S.D.

0.7

10

0.8

20

1.8

23

|

Subject

1

|

1

4.3

1

2

1

j

i

%pred

1
1
1
|1
1
11
1
i1
1
11
1
|1
1
1
1
1
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
i
1
1
1
1
1
1
1
i
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TABLE 6
Baseline Pulmonary Function Testing

Vmax50%

MEF40%

MEF40%(P)

Subject

1/sec

%pred

1/sec

1/sec

1

5.7

129

4.3

2.6

2

1.3

31

1.0

0.9

3

2.0

50

1.4

1.4

4

3.2

79

2.4

1.6

5

2.0

38

1.6

1.5

6

3.3

67

2.4

2.1

7

1.8

45

1.4

0.8

8

2.9

57

2.4

2.1

9

2.7

51

2.2

2.7

10

4.1

83

3.0

2.8

11

4.3

83

3.6

2.9

12

4.9

107

4.1

4.1

Mean

3.2

69

2.5

2.1

S.D.

1.4

30

1.1

1.0
j
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TABLE 7
Comparison of Baseline FEV1

l

C + Indo

Subject

Screen

Placebo

Vit C

Indocin

1

3.9

3.5

3.8

3.5

3.7

2

1.9

2.0

2.1

2.1

2.2

3

2.2

2.0

2.0

2.2

2.0

4

3.0

2.9

3.1

2.9

3.0

5

2.9

2.5

2.5

2.6

2.5

6

3.2

3.6

3.6

3.5

3.6

7

2.3

2.1

2.0

2.1

2.1

8

3.5

3.8

3.8

3.9

3.7

9

3.2

2.9

2.8

3.0

3.4

10

3.9

3.6

3.8

3.6

3.8

11

4.1

3.9

4.1

4.1

3.8

12

4.2

4.1

4.3

4.1

3.9

Mean

3.2

3.1

3.2

3.1

3.1

S.D.

0.8

0.8

0.8

0.8

0.7
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TABLE 8
Comparison of Baseline MEF40%(P)

1
1
|
|
1
|
i
1
1
i
1
1
l
1
1
1
1
|
l
1
1
l
1
1
l
1
1
l
1
1
1

Subject

Screen

Placebo

Vit C

Indocin

1

2.6

4.1

4.4

4.2

4.4

2

0.9

0.8

0.8

1.0

1.0

3

1.4

0.9

0.5

0.9

0.5

4

1.6

1.1

1.3

1.6

1.2

5

1.5

1.0

1.1

0.9

1.0

6

2.1

2.6

2.8

2.2

1.5

7

0.8

0.5

0.5

0.4

0.4

8

2.1

1.9

1.9

2.0

2.1

9

2.7

1.6

1.2

1.4

1.9

1
1
1
1
1

io

2.8

2.1

2.5

2.6

2.1

11

2.9

4.2

3.3

4.5

4.3

1
1
1
|
1
1
|
1
i

12

4.1

2.7

2.6

2.8

2.0

Mean

2.1

2.0

1.9

2.0

1.9

S.D.

1.0

1.2

1.2

1.3

1.3

-1
1
1
il
1
1
1
1
1
1
1
1
1
1
1
1
1
l
1
1
l
1
1
1
1
1
1
1
1
1
1
1
i
1
1
1
1
1
1
1
1
i
1
1
1
i

C + Indo

Tables 9 through 16 display the raw data for FEV1 and MEF40%(P)
all time points on all five of the study days.
number of minutes after the completion
other values

are as follows :

"Base "

"Rest" = value two hours after drug

for

(The times given are the

of the exercise challenge.
= value prior to

The

drug ingestion,

ingestion and prior to the exercise

44
challenge, and "P.A." = post-alupent,

value after subjects received me-

taproterenol upon completing the exercise challenge.)
The mean values for the group are plotted over time in Figures 3 and
4.

These

figures graphically demonstrate the

subjects and how there was very little
drugs.

There

was still significant

minutes post-exercise (using both the
baseline)

course of EIB

in these

variation produced by any of the
bronchospasm at five

and fifteen

absolute and percent changes from

for almost all parameters as on

the screening day (P < .05).

The only data that varied much from the screening day was the FVC on the
day that the subjects received
On that particular

day,

ascorbic acid and indomethacin together.

the FVC was decreased significantly

(P < .05)

from baseline at all time points from one to sixty minutes post-exercise
(absolute and

percent changes).

This

is markedly different

from the

screening day where only the five minute point achieved statistical sig¬
nificance .

44a

FIGURE 3

FEV, (L/sec)

FEV,-MEAN OF ALL SUBJECTS

44b
FIGURE 4

MEF4o%(P)(L/sec)

MEF40o/fe(P)-MEAN OF ALL SUBJECTS
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TABLE 9
FEV1 - Placebo Day

Subject Base Rest lmin 5min 15min 30min 60min P.A
1

3.5

3.4

3.7

3.5

3.5

3.5

3.5

3.4

2

2.0

2.2

2.2

1.8

1.8

2.1

2.1

2.6

3

2.0

2.1

1.9

1.2

1.1

1.7

2.0

2.5

4

2.9

3.0

2.8

2.8

2.8

3.0

2.8

3.2

5

2.5

2.7

2.2

2.3

2.2

2.7

2.5

3.2

6

3.6

3.4

2.8

2.6

2.5

3.2

3.5

3.9

7

2.1

2.1

2.0

2.0

2.0

2.2

2.2

2.4

8

3.8

3.7

4.0

3.6

3.6

3.7

3.7

3.9

9

2.9

3.0

2.3

2.3

2.3

2.7

3.0

3.6

10

3.6

3.5

3.3

3.3

3.4

3.5

3.7

4.0

11

3.9

3.8

4.0

3.8

3.7

3.8

3.9

4.0

12

4.1

4.1

4.1

4.2

4.0

4.0

4.0

4.0

Mean

3.1

3.1

2.9

2.8

2.7

3.0

3.1

3.4

S.D.

0.8

0.7

0.8

0.9

0.9

0.7

0.7

0.6
j
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TABLE 10
FEV1 - Placebo + Vitamin C Day

Subject Base Rest lmin 5min 15min 30min 60min P. A

L

1

3.8

3.5

3.9

3.8

3.8

3.7

3.6

3.6

2

2.1

2.0

2.1

1.7

1.7

2.0

2.2

2.6

3

2.0

2.0

1.5

1.1

1.0

1.3

1.7

2.4

4

3.1

3.0

3.1

2.9

2.9

3.0

3.1

3.2

5

2.5

2.9

2.5

2.2

2.6

2.9

2.8

3.3

6

3.6

3.7

3.6

3.6

3.5

3.6

3.7

3.9

7

2.0

2.1

2.0

1.9

2.0

2.1

2.1

2.3

8

3.8

3.9

3.8

3.8

3.9

4.0

4.0

4.2

9

2.8

3.2

2.5

2.4

2.8

2.6

3.1

3.8

10

3.8

3.7

3.5

3.5

3.6

3.7

3.7

4.1

11

4.1

3.9

4.1

3.9

3.9

3.7

3.9

4.0

12

4.3

4.1

4.3

4.2

4.2

4.2

4.1

4.2

Mean

3.2

3.2

3.1

2.9

3.0

3.1

3.2

3.5

S.D.

0.8

0.8

0.9

1.0

1.0

0.9

0.8

0.7
J
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TABLE 11
FEV1 - Placebo + Indomethacin Day

Subject Base Rest Imin 5min 15min 30min 60min P.A
1

3.5

3.4

3.6

3.4

3.4

3.3

3.3

3.4

2

2.1

2.2

2.6

2.0

2.0

2.1

2.1

2.6

3

2.2

1.9

1.5

1.1

1.0

1.4

1.7

2.4

4

2.9

3.0

3.0

3.0

3.0

3.2

3.0

3.3

5

2.6

3.0

2.7

2.4

2.5

2.7

2.6

3.4

6

3.5

3.7

3.2

3.1

3.0

3.2

3.4

3.8

7

2.1

2.1

2.1

2.0

2.1

2.1

2.2

2.3

8

3.9

3.9

4.1

4.0

3.7

4.1

4.1

4.2

9

3.0

3.1

2.2

2.2

2.3

2.6

3.1

3.8

10

3.6

3.8

3.5

3.3

3.6

3.5

3.6

4.0

11

4.1

3.7

3.9

3.8

4.0

3.8

3.7

4.1

12

4.1

4.0

4.2

4.2

4.2

4.2

4.2

4.1

Mean

3.1

3.2

3.0

2.9

2.9

3.0

3.1

3.4

S.D.

0.8

0.7

0.9

0.9

0.9

0.9

0.8

0.7
j
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TABLE 12
FEV1 - Vitamin C + Indomethacin Day

Subject Base Rest lmin 5min 15min 30min 60min P.A.
1

3.7

3.6

3.6

3.5

3.4

3.4

3.6

3.6

2

2.2

2.1

2.2

1.7

1.6

1.9

1.9

2.3

3

2.0

1.9

1.8

1.3

1.2

1.5

1.7

2.5

4

3.0

3.0

2.8

2.7

2.6

2.8

2.7

3.2

5

2.5

2.7

2.1

1.7

2.0

2.1

2.4

2.9

6

3.6

3.5

3.1

2.6

2.3

3.0

3.4

3.8

7

2.1

2.2

2.1

1.8

2.0

2.0

2.1

2.3

8

3.7

3.7

4.1

4.0

3.8

3.9

4.0

4.0

9

3.4

3.4

3.0

3.0

2.8

3.0

3.0

3.7

10

3.8

3.7

3.4

3.4

3.5

3.6

3.6

4.1

11

3.8

3.8

3.8

3.7

4.0

3.8

3.8

3.9

12

3.9

4.0

4.2

4.1

4.0

4.2

4.2

4.4

Mean

3.1

3.1

3.0

2.8

2.8

2.9

3.0

3.4

S.D.

0.7

0.7

0.8

1.0

1.0

0.9

0.9

0.7
j
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TABLE 13
MEF40% (P) - Placebo Day

Subject Base Rest lmin 5min 15min 30min 60min P. A

L

1

4.1

3.4

3.5

3.7

3.3

3.4

3.4

3.9

2

0.8

1.0

1.1

0.6

0.6

0.8

1.2

2.0

3

0.9

1.1

0.6

0.2

0.2

0.4

0.9

1.8

4

1.1

1.6

1.2

0.9

1.2

1.5

1.3

2.4

5

1.0

1.3

0.7

0.7

0.8

1.4

0.9

1.9

6

2.6

2.0

0.9

0.6

0.6

1.6

2.4

3.9

7

0.5

0.5

0.4

0.4

0.3

0.5

0.6

1.0

8

1.9

2.0

2.5

1.8

1.7

1.9

2.2

2.7

9

1.6

2.0

0.4

0.4

0.6

1.1

2.0

3.5

10

2.1

1.9

1.2

1.2

1.7

2.1

2.3

4.5

11

4.2

4.5

4.1

4.2

3.6

4.2

4.1

4.6

12

2.7

3.1

2.9

2.9

2.8

3.0

3.0

4.8

Mean

2.1

2.0

1.6

1.5

1.4

1.8

2.0

3.1

S.D.

1.0

1.1

1.3

1.4

1.2

1.2

1.1

1.3
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TABLE 14
MEF40%(P) - Placebo + Vitamin C Day

Subject Base Rest lmin 5min 15min 30min 60min P.A
1

4.4

3.7

3.7

2.9

3.3

3.5

3.7

5.0

2

0.8

1.0

0.9

0.3

0.4

0.6

0.9

1.0

3

0.5

0.2

0.2

0.1

0.0

0.1

0.3

1.4

4

1.3

1.6

1.6

1.1

1.2

1.5

1.7

2.3

5

1.1

1.6

1.0

0.7

1.1

1.5

1.2

2.0

6

2.8

2.9

1.7

1.8

1.8

2.7

2.7

4.0

7

0.5

0.9

0.4

0.3

0.5

1.0

0.8

1.7

8

1.9

2.0

2.1

2.0

1.8

2.1

2.2

2.8

9

1.2

1.9

0.6

0.6

1.0

1.2

1.4

3.1

10

2.5

2.3

1.5

1.7

2.2

2.3

2.3

4.1

11

3.3

3.5

3.3

3.2

3.6

3.6

3.6

4.3

12

2.6

2.4

2.8

2.3

2.6

2.5

2.6

3.7

Mean

1.9

2.0

1.6

1.4

1.6

1.9

2.0

3.0

S.D.

1.2

1.0

1.1

1.1

1.1

1.1

1.1

1.3
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TABLE 15
MEF40%(P) - Placebo + Indomethacin Day

Subject Base Rest lmin 5min 15min 30min 60min P.A
1

4.2

4.4

3.9

3.1

3.3

3.2

3.7

5.0

2

1.0

0.9

1.8

0.9

0.8

1.2

0.9

1.3

3

0.9

0.6

0.3

0.2

0.2

0.3

0.5

1.0

4

1.6

1.5

1.8

1.5

1.7

2.1

1.9

3.4

5

0.9

1.4

1.1

0.7

0.8

1.0

0.9

2.2

6

2.2

2.6

1.3

0.8

1.1

1.5

1.8

3.9

7

0.4

1.0

0.5

0.3

0.6

0.8

0.7

1.5

8

2.0

1.9

2.4

1.9

1.8

2.4

2.4

2.9

9

1.4

1.9

0.2

0.2

0.4

0.7

1.3

2.9

10

2.6

2.8

2.2

1.7

2.2

1.8

2.7

4.0

11

4.5

4.5

4.4

4.3

4.2

4.3

4.3

4.6

12

2.8

3.3

3.5

3.2

3.3

3.3

3.3

3.3

Mean

2.0

2.2

2.0

1.7

1.8

1.9

2.0

3.0

S.D.

1.3

1.3

1.4

1.3

1.3

1.2

1.3

1.3
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TABLE 16
MEF40%(P) - Vitamin C + Indomethacin Day

Subject Base Rest lmin 5min 15min 30min 60min P. A

L

1

4.4

3.6

3.3

2.5

2.8

2.8

3.1

4.4

2

1.0

0.8

0.8

0.4

0.3

0.4

0.7

1.4

3

0.5

0.6

0.3

0.2

0.2

0.3

0.3

1.4

4

1.2

1.4

1.0

0.9

0.9

1.2

1.0

2.2

5

1.0

1.1

0.7

0.3

0.5

0.6

0.9

1.5

6

1.5

1.4

0.7

0.4

0.3

0.9

1.5

3.1

7

0.4

0.5

0.4

0.2

0.3

0.6

0.5

1.1

8

2.1

2.2

3.1

2.6

2.5

2.8

2.7

3.2

9

1.9

2.3

1.0

1.1

1.2

1.5

1.9

3.0

10

2.1

2.0

1.3

1.4

1.3

1.5

1.6

2.8

11

4.3

4.4

4.4

4.5

4.6

4.4

4.4

4.8

12

2.0

2.3

2.7

2.6

2.6

2.8

2.7

4.0

Mean

1.9

1.9

1.6

1.4

1.7

2.0

1.8

2.7

S.D.

1.3

1.2

1.4

1.4

1.4

1.8

1.2

1.2
j
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Comparisons between
Methods section.

the drug

days were

made as

described in

the

There were no significant differences between the ef¬

fects of ascorbic acid and placebo on the response to exercise (P > .05)
at any of the time points.
ences between the
combination of

Likewise,

there were no significant differ¬

effects of indomethacin and

ascorbic acid and

placebo.

However,

indomethacin did produce

yet statistically significant, differences from placebo.

the

some small,

This drug com¬

bination produced a decrement in the FVC that was 0.2 1/sec (or approxi¬
mately 5%) lower than the placebo values at 30 and 60 minutes post-exer¬
cise and after the metaproterenol.

Despite this, comparing the ascorbic

acid and indomethacin combination to ascorbic

acid alone did not demon¬

strate any statistically significant differences.
In addition
study was

to looking at

also able

to assess

the effects of
their effects

This was accomplished by comparing the
tables) with the post-drug,

the drugs on
on resting

EIB,

this

airway tone.

pre-drug baseline ("Base" in the

resting PFT's done before the exercise chal¬

lenge ("Rest" in the tables).

None of the drug combinations had a sig¬

nificant effect on resting lung function (all P values >

.05).

Figure 5 illustrates the FEV1 curves for three subjects in the group
•who had less

EIB on the days

three subjects

when ascorbic acid was

the suggested "protective

given.

action" of ascorbic

peared to be blocked by the addition of indomethacin.
jects appeared

to have

worse EIB after

treatment with

In these
acid ap¬

Three other sub¬
ascorbic acid,

while six subjects appeared to have EIB of the same severity with ascor¬
bic acid.

Indomethacin alone did not

of the subjects,

have a significant effect on any

regardless of their response to

ascorbic acid.

The

54
three subjects who
from the

responded favorably to ascorbic acid

other subjects in

terms of

age, sex, history of allergies, asthma,

any of the

following parameters:

or EIB,

or severity or pattern

of EIB response to screening exercise challenge.
subjects did have more severe asthma
as percent of predicted.

age FEV1 that was 96% of predicted.

for FVC,

PEFR,

However,

these three

as measured by their baseline FEV1

The ascorbic acid responders had an FEV1 that

was, on average, 75% of predicted.

responders had

did not differ

The other nine subjects had an aver¬
Similarly, the three ascorbic acid

lower percent predicted
and Vmax50%.

The

values than the

other subjects

three subjects who appeared to have

worse EIB after ascorbic acid treatment

could not be distinguished from

the six non-responders using any of the above parameters.

54a

FIGURE 5
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IX
DISCUSSION

9.1

RESPONSE TO EXERCISE WITHOUT DRUGS

Data from the initial

screening day of the study documented

twelve subjects on the

basis of at least a 20%

baseline at some point after exercise.
into two
1978a).

groups based on the

EIB in all

drop in MEF40%(P)

from

These subjects may be separated

criterion of Schachter et

al (Schachter,

It was in that study that the researchers were able to separate

subjects with EIB into two groups:
1.

One group with decreased air flow

using measures of small airway

status (MEF40% and MEF40%(P)) and
2.

A second

group with decreased flow

according to both

small and

large (FEV1) airway parameters.
In the present study six subjects had post-exercise decreases in FEV1 of
at least 10%

on the screening challenge,

did not decrease their FEV1 by that much.
firms the observation

while the

other six subjects

This study,

that two distinct patterns

therefore,

con¬

of airway obstruction

in EIB can be described.
One somewhat unexpected

finding in the screening data

was that the

subjects as a group showed significant bronchospasm as early as one min¬
ute after exercise, with MEF40%(P)
baseline to 1.6

+/- 1.0 1/sec at

with bronchoconstriction

decreasing from 2.1 +/- 1.0 1/sec at
one minute.

beginning about

55

EIB has

five minutes

been described
after exercise,

56
preceded
1983).

by

bronchodilatation

However,

immediately

post-exercise

(McFadden,

one must recall that each time point in this study is

actually the mean of three PEFV and MEFV curve maneuvers done one minute
apart.

Thus,

the value for the one minute post-exercise point is really

the mean of three values obtained at one,
exercise.

Suspecting that taking the

two,

and three minutes post¬

mean of these three measurements

might have obscured the initial bronchodilatation because of subsequent,
progressive bronchoconstriction in the later values,
re-examined.

the MEF40%(P)

This was done using the data from the screening day,

ing at the individual curves that made up each time point.
three curves did

demonstrate a progressive decline

was
look¬

Indeed,

in MEF40%(P),

the
with

the individual values being:
1.

One minute post-exercise = 1.8 +/- 1.0 1/sec,

2.

Two minutes post-exercise = 1.6 +/- 1.1 1/sec, and

3.

Three minutes post-exercise = 1.4 +/- 0.9 1/sec.

Even the

first value,

baseline,

however respresents a

but this did not achieve

It may be that the

0.3 1/sec

decrease from

statistical significance (P >

.10).

post-exercise bronchodilatation is quite short-lived

and was not picked up in this study

because the first value was not ob¬

tained until a full minute after exercise had ceased.

Two studies using

exercise challenges and PFTs the most similar to this study also did not
demonstrate

significant

bronchodilatation

(Schachter, 1978a and Schachter,
studies,

the

1982).

In fact,

only value reaching statistical

after exercise was a decrease in FVC.

immediately

post-exercise

in the latter of these

significance immediately
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All PFTs

demonstrated a bronchodilating response

to metaproterenol

(except FVC) as expected.

9.2

RESPONSE TO EXERCISE WITH DRUGS

This study

was designed

to confirm the

protective effect

of ascorbic

acid in EIB and to examine the mechanism of such an effect.

Our working

hypothesis was that this effect was
din metabolism.

due to an alteration in prostaglan¬

It was expected that

this protection would be blocked

by the simultaneous administration of indomethacin, as had been shown to
be the

case with methacholine

Mohsenin,

1983).

However,

induced bronchospasm (Ogilvy,

1981 and

the present study failed to confirm the exis¬

tence of a protective effect of

ascorbic acid against EIB.

There were

some trends in the data suggesting a possible benefit at fifteen minutes
post-exercise, with the FEV1 5% and MEF40%(P)
with ascorbic acid than with placebo.

respectively,

Neither of these values, however,

achieved statistical significance (P = .14
The FVC was only 0.5% better for

9% better,

and P = .11,

respectively).

ascorbic acid than placebo at the same

time point.

These findings are in contrast to Schachter and Schlesinger

(Schachter,

1982)

ters and at

all times measured (immediate

who found the protective effect trend in all parame¬

post-exercise, and after metaproterenol).
nificance in

their study were those

post-exercise,

five minutes

The values that achieved sig¬

reflecting a protective

the bronchoconstriction of larger airways (FEV1 and FVC).

effect on

Our work does

not support these earlier results.
It should

be noted that when

individual subjects were

examined in

this earlier study only eight out of the twelve subjects showed less EIB

58
when ascorbic acid was administered.
dividuals had more
than a 10%

Of these eight subjects,

significant benefit from the

improvement in FEV1 at five minutes

pared to the response to placebo).

ascorbic acid (greater
post-exercise when com¬

These five subjects,

bic acid responders in our study,

like the ascor¬

had a lower percent predicted of FEV1

than the other subjects in the study (63% and 83% of predicted,
tively).

five in¬

respec¬

Thus, it may be that those subjects with a lower percent pre¬

dicted of FEV1 are more likely to derive benefit from treatment with as¬
corbic acid.

Furthermore,

between our results
number

a possible

and those of the

of "ascorbic

explanation for the differences
earlier study may be

acid responders"

in

Schachter and

the greater
Schlesinger1s

group.
The five subjects
greatest response

in Schachter and Schlesinger1s study

to ascorbic acid

other subjects by their more severe
lenge.

were also distinguishable

airway status.

the PFTs that reflect both

The ascorbic acid

responders had mean

FEV1 and MEF40%(P) of 78% and 42% of their baseline values,
ly, at five minutes post-exercise.
and MEF40%(P)

of

89% and 62%,

respectively,

at the

suggest that
lower baseline

In our study the responders had five

65% of baseline.

ascorbic acid responders may
FEV1

(as percent

same time point.

responders and non-responders was

minute FEV1 and MEF40%(P) values of 93% and 64%,
ers had values that were 93% and

respective¬

The remaining subjects had mean FEV1

This difference between ascorbic acid
not evident in the present study.

from the

EIB on the screening exercise chal¬

This characteristic was apparent in

large and small

who had the

while the non-respond¬
Thus,

both studies

be those individuals

of predicted value).

However,

with a
this
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study does not confirm the finding in the earlier investigation that as¬
corbic acid responders

are also those who

experience greater bronchos-

pasm in response to exercise.
There are really very few differences
one used by Schachter and Schlesinger.
drug combinations and

studies.

This study looked at additional

carried the measurement of PFTs out

period of time after exercise ended.
themselves were

between this protocol and the

carried out in

for a longer

The exercise challenges and PFTs

virtually the

same fashion in

the two

This study had subjects wait two hours between drug ingestion

and exercise challenge,
ute waiting

period.

while the earlier study utilized only a 90 min¬
This

is probably

since our study gave subjects 750

not a

significant difference,

mg of ascorbic acid,

while Schachter

and Schlesinger1s subjects ingested only 500 mg.
The next thing to examine for
is the subjects
difference in the

themselves.

differences between these two studies

Already mentioned above

was the apparent

number of "ascorbic acid responders"

studies and the difference in the
ers" in these investigations.
may also be reflected

between the two

severity of EIB between the "respond¬

The difference in number of "responders"

in this study group appearing to

healthier baseline than the previous study group,
PEFR close to predicted values (102%, 90%,

have a slightly

with FVC,

and 94%,

respectively),

opposed to the earlier group where these parameters were 87%,
78% of predicted.
identical:

75%,

and
as
and

The baseline MEF40%(P) for the two cohorts was almost

2.1 +/- 1.0 and 2.1 +/- 1.1 1/sec.

urements are also

FEV1,

quite similar.

There are no

guishing these two study populations.

Many of the other meas¬
strong factors distin¬
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Another possible explanation for the
ies lies in a phenomenon alluded
airway obstruction in EIB,
asthmatics.

different results in the stud¬

to earlier:

possibly

defining two distinct subgroups of

The study by Schachter et al describing these two patterns

of airway response to exercise (Schachter,
that has revealed such a dichotomy in
fects of

two different patterns of

EIB.

various pharmacological agents

This group of subjects

is not the only work

Studies looking at the ef¬

on EIB have

some subjects have the predominant site
eral airways.

1978a)

demonstrated that

of obstruction in their periph¬
had EIB attenuated by DSCG,

did not derive any benefit from anticholinergic agents (McFadden,
and Thomson,

1978).

but
1977b

Conversely, a small group of subjects are protected

from EIB by atropine and not by

DSCG (Godfrey,

1976).

There is yet a

third subpopulation whose main site of obstruction is in the larger airways, yet they have less EIB when given either DSCG or ipratropium brom¬
ide (another anticholinergic agent)

(McFadden,

1977b and Thomson,

1978).

Further evidence for dual mechanisms in EIB is provided by a study where
ipratropium provided protection against
nic hyperventilation
after many such
drug.

bronchospasm induced by isocap-

in subjects who normally

experienced bronchospasm

challenges repeated over a short

interval without this

Subjects who did not continue to have bronchospasm after repeated

challenges (analogous to the refractory period
from ipratropium (Wilson, 1982).
work is one

in EIB)

did not benefit

The hypothesis that emerges from this

where EIB actually may develop by

two different mechanisms

in different subjects:
1.

A peripheral

airway response that

responds to DSCG and

is from mediator

release and
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2.

A central

airway response that is

mediated by reflexes

and re¬

sponds to anticholinergic medications.
The existence

of such heterogeneity may

produced conflicting results when they

help explain why

studies have

have examined only one mechanism

or the other at any single time.
In the present study we were unable to demonstrate a therapeutic ef¬
fect of ascorbic acid for the group
statistically significant,
did appear to have
Figure 5.

there

of subjects as a whole.
was a subgroup of

While not

three subjects who

their EIB attenuated by ascorbic acid,

In this group the

with our hypothesis.

response to indomethacin

This raises the

as shown in
was consistent

possibility that the response to

ascorbic acid may be another factor that can distinguish different types
of asthmatics, possibly related to the different proposed mechanisms for
EIB.

In this small group of responders to ascorbic acid, however,

were no clear

trends in small or large airway

there

patterns identified that

would suggest where ascorbic acid might be having its effect.

Schachter

and Schlesinger's data supports an effect of ascorbic acid on large air¬
ways because FEV1

and FVC were the parameters that

tive effect

statistically significant

This would be

on a

consistent with a role

indicated a protec¬

level (Schachter,

for ascorbic acid in

1982).

the vagally

mediated type of larger airway bronchospasm, and is further supported by
work on the effect of ascorbic acid on methacholine induced bronchospasm
and Mohsenin,

1983).

thacholine is blocked

Since the protection of ascorbic acid against me¬
by indomethacin,

one would have

to postulate an

even more complex interaction between ascorbic acid, prostaglandins, and
the cholinergic nervous

system.

(Of course,

this might

be even more
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complicated given the trends in our

study showing some effect of ascor¬

bic acid on smaller airway parameters as well.)
Our results demonstrating

no effect of either ascorbic

acid or in-

domethacin on baseline airway tone agree with the earlier studies (Ogilvy,

1981, Schachter,

1982, and Mohsenin,

tion that if ascorbic acid has

1983).

This supports the no¬

a therapeutic effect,

it probably works

on a dynamic process in EIB, such as prostaglandin generation.
What is clear from the above discussion is the need for studies uti¬
lizing a larger number of subjects to
the identification
ascorbic acid.

of a subgroup of

look at ascorbic acid and EIB and
asthmatics that are

The magnitude of the effect

subgroup remains to be determined,
the previous study

but

responsive to

of ascorbic acid in such a

the experience in our study and

of Schachter and Schlesinger suggest that

it is not

very great.
Another promising direction

in this research is

the inhibitors of the various steps
Wauwe,

1983 and Weichman,

in animal

1984).

studies and then human

the development of

in arachidonic acid metabolism (Van
Once such agents are adapted for use
clinical trials,

one will

be better

able to tease apart the relative contributions of leukotrienes and pros¬
taglandins to EIB and how ascorbic acid may influence these pathways.

BIBLIOGRAPHY

1. Adams, F.
The Extant Works of Aretaeus the Cappadocian.
Soc (London) 1856, p.316.

Syndenham

2. Adkinsin, N.F. Jr., Newball, H.H., Findlay, S., Adams, G.K., and
Lichtenstein, L.M.
Origin of PGF2* production following
anaphylactic challenge of human lung.
Monogr Allergy 14: 122-125,
1979.

3. Adkinson, N.F. Jr., Newball, H.H., Findlay, S., Adams, G.K., and
Lichtenstein, L.M.
Anaphylactic release of prostaglandins from
human lung in vitro.
Amer Rev Resp Dis 121: 911-920, 1980.

4.

Allegra, J., Trautlein, J., Demers, L., Field, J., and Gillin, M.
Peripheral plasma determinations of prostaglandin E in asthmatics.
J Allergy Clin Immunol 58: 546, 1976.

5.

American Thoracic Society.
Definition and classification of
chronic bronchitis, asthma, and pulmonary emphysema.
Amer Rev Resp
Dis 85: 762-768, 1962.

6. Anah, C.O., Jarike, L.N., and Baig, H.A.
High dose ascorbic acid
in Nigerian asthmatics.
Trop Geogr Med 32: 132-137, 1980.

7. Anderson, R., Hay, I., Van Wyk, H.A., and Theron, A.
in bronchial asthma.
S Afr Med J 63: 649-652, 1983.

Ascorbic acid

8. Anderson, S.D., Bye, B.T.P., Schoeffel, R.E., Scale, J.P., Taylor,
K.M., and Ferris, L.
Arterial plasma histamine levels at rest,
during and after exercise in patients with asthma: effects of
terbutaline aerosol.
Thorax 36: 259-267, 1981.

9. Anderson, S.D., McEvoy, D., and Bianco, S.
Changes in lung volumes
and airway resistance after exercise in asthmatic subjects.
Amer
Rev Resp Dis 106: 30-37, 1972.

63

64
10. Anderson, S.D., Pojer, R., Smith, I.D., and Temple, D.
Exercise
related changes in plasma levels of
15-keto-13,14-dihydroprostaglandin F2* and noradrenaline in
asthmatic and normal subjects.
Scand J Resp Dis 57: 41-48, 1976.

11. Anderson, S.D., Silverman, M., Konig, P., and Godfrey, S.
Exercise-induced asthma.
Brit J Dis Chest 69: 1-39, 1975.

12. Atkins, P.C., Norman, M., Weiner, H., and Zweiman, B.
Release of
neutrophil chemotactic activity during immediate hypersensitivity
reactions in humans.
Ann Int Med 86: 415-418, 1977.

13. Austen, K.F.
Reactive mechanisms in the release of mediators of
immediate hypersensitivity from human lung tissue.
Fed Proc 33:
2256, 1974.

14. Barnes, P.J. and Brown, M.J.
Venous plasma histamine in exercise
and hyperventilation-induced asthma in man.
Clin Sci 61: 159-162,
1981.
( = Barnes, 1981a).

15. Barnes, P.J., Brown, M.J., Silverman, M., and Dollery, C.T.
Circulating catecholamines in exrcise and hyperventilation induced
asthma.
Thorax 36: 435-440, 1981.
( = Barnes, 1981b).

16.

Bar-Or, 0., Neuman, I., and Dotan, R.
Effects of dry and humid
climates on exercise-induced asthma in children and preadolescents.
J Allergy Clin Immunol 60: 163-168, 1977.

17.

Beil, M., Brecht, H.M., and Rasche, B.
Plasma catecholamines in
exercise induced bronchoconstriction.
Klin Wschr 55: 577-581,
1977.

18. Benfey, B.G.
The evidence against interconversion of alpha- and
beta-adrenoceptors.
Trends Pharmacol Sci 1: 193-194, 1980.

19. Bianco, S., Griffin J.P., Kamburoff, P.H., et al.
Prvention of
exercise-induced asthma by indoramin.
Brit Med J 4: 18-20, 1974.

20. Biel, M. and de Kock, M.A.
Role of alpha-adrenergic receptors in
exercise-induced bronchoconstriction.
Respiration 35: 78-86, 1978.

65

.

21

Bouhuys, A., Hunt, V.R., Kim, B.M., and Zapletal, A.
Maximum
expiratory flow rates in induced bronchoconstriction in man.
J
Clin Invest 48: 1159-1168, 1969.

22. Bouhuys, A.
Flow volume curves.
In:
The Physiology of Breathing.
Grune and Stratton (New York) 1976, pp. 202-232.

23. Breslin, F.J., McFadden, E.R. Jr., and Ingram, R.H. Jr.
The effect
of cromolyn sodium on the airway response to hyperpnea and cold air
in asthma.
Amer Rev Resp Dis 122: 11-16, 1980.
( = Breslin,
1980a).

24. Breslin, F.J., McFadden, E.R. Jr., Ingram, R.H. Jr., and Deal, E.C.
Jr.
Effects of atropine on respiratory heat loss in asthma.
J
Appl Physiol 48: 619-623, 1980.
( = Breslin, 1980b).

25. Brocklehurst, W.E.
The release of histamine and formation of a
slow reacting substance of anaphylaxis (SRS-A) during anaphylactic
shock.
J Physiol 151: 416-435, 1960.

26. Capel, L.H. and Smart, J.
The forced expiratory volume after
exercise, forced inspiration, and the Valsalva and Muller
manoeuvres.
Thorax 14: 161, 1959.

27. Carsten, M.
Prostaglandin's part in in regulating uterine
contraction by transport of calcium.
In:
The Prostaglandins.
Wouthern, E. editor.
Futura Pub Co (New York) 1972, pp. 59-66.

28. Cerrina, J., Denjean, A., Alexandre, G., Lockhart, A., and Duroux,
P.
Inhibition of exercise-induced asthma by a calcium antagonist,
nifedipine.
Amer Rev Resp Dis 123: 156-160, 1981.

29. Chan-Yeung, M.M.W., Vyas, M.N., and Gryzbowski, S.
Exerciseinduced asthma.
Amer Rev Resp Dis 104: 915-923, 1971.

30. Chatterjee, I.B., Das Gupta, S., Majumder, A.K., Nandi, B.K., and
Subramanian, N.
Effect of ascorbic acid on histamine metabolism in
scorbutic guinea pigs.
J Physiol 251: 271, 1975.

31. Chen, W.Y. and Horton, D.J.
in exercise induced asthma.

Heat and water loss from the airways
Respiration 34: 305-313, 1977.

66
32. Chryssanthopoulos, C., Barboriak, J.J., Fink, J.N., Stekiel, W.J.,
and Maksud, M.G.
Adrenergic responses of asthmatic and normal
subjects to submaximal and maximal work levels.
J Allergy Clin
Immunol 61s 17-22, 1978.

33. Cockcroft, D.W., Killian, D.N., Adrian-Mellon, J.J., and Hargreave,
F.E.
Protective effect of drugs on histamine-induced asthma.
Thorax 32: 429, 1977.

34. Corey, E.J., Clark, D.A., Goto, G., Marfat, C., Mioskowski, C.,
Samuelsson, B., and Hammarstrom, S.
Stereospecific total synthesis
of a slow reacting substance of anaphylaxis, leukotriene C-l.
J Am
Chem Soc 102: 1436, 1980.

35. Crompton, G.K.
An unusual example of exercise-induced asthma.
Thorax 23: 165-167, 1968.

36. Cropp, G.J.A.
and Schmultzler, I.J.
Grading, time course, and
incidence of exercise-induced airway obstruction and hyperinflation
in asthmatic children.
Pediatrics (suppl.) 56: 868, 1975.

37. Dahlen, S.E., Hedqvist, P., Hannarstrom, S., and Samuelsson, B.
Leukotrienes are potent constrictors of human bronchi.
Nature 288:
484-486, 1980.

38. Danford, D.E. and Munro, H.N.
Ascorbic acid (Vitamin C).
Chap.
66, Water-soluble vitamins.
The vitamin B complex and ascorbic
acid.
In:
The Pharmacological Basis of Therapeutics.
Gilman,
A.G., Goodman, L.S., and Gilman, A.
MacMillan Pub Co (New York)
1980, pp. 1576-1580.

39. Dawson, W., Hemsworth, B.A., and Stockham, M.A.
Actions of sodium
ascorbate on smooth muscle.
Brit J Pharmacol 31: 268, 1967.

40. Dawson, W., Starr, M.S., and West, G.B.
Inhibition of anaphylactic
shock in the rat by antihistamine and ascorbic acid.
Brit J
Pharmacol 27: 249, 1966.

41. Dawson, W. and West, G.B.
The influence of ascorbic acid on
histamine metabolism in guinea pigs.
Brit J Pharmacol 24: 725,
1965.

67
42.

Deal, E.C. Jr., McFadden, E.R. Jr., Ingram, R.H. Jr., and Jaeger,
J.J.
Effects of atropine on potentiation of exercise-induced
bronchospasm by cold air.
J Appl Physiol 45: 238-243, 1978.

43. Deal, E.C. Jr., McFadden, E.R. Jr., Ingram, R.H. Jr., and Jaeger,
J.J.
Esophageal temperature during exercise in asthmatic and non
asthmatic subjects.
J Appl Physiol 46: 484-490, 1979.
( = Deal,
1979a).

44. Deal, E.C. Jr., McFadden, E.R. Jr., Ingram, R.H. Jr., Strauss,
R.H., and Jaeger, J.J.
The role of respiratory heat exchange in
the production of exercise-induced asthma.
J Appl Physiol 46:
467-475, 1979.
( = Deal, 1979b).

45. Deal, E.C. Jr., Wasserman, S.I., Soter, N.A., Ingram, R.H., and
McFadden, E.R. Jr.
Evaluation of role played by mediators of
immediate hypersensitivity in exercise-induced asthma.
J Clin
Invest 65: 659-665, 1980.

46. Edmunds, A.T., Tooley, M., and Godfrey, S.
The refractory period
after exercise-induced asthma: Its duration and relation to the
severity of exercise.
Amer Rev Resp Dis 117: 247-254, 1978.

47. Engstrom, I., Karlberg, P., Krapelien, S., and Wengler, G.
Respiratory adaptations during exercise tolerance tests with
special reference to mechanical properties of lungs in asthmatics
and healthy children.
In: Respiratory Studies in Children.
Acta
Paediat 49: 850, 1960.

48. Enright, P.L. and Souhrada, J.F.
Effect of lidocaine anesthesia on
the ventilatory response of asthmatics to exercise.
Amer Rev Resp
Dis 122: 823-828, 1979.

49. Fanta, C.H., Ingram, R.H. Jr., and McFadden, E.R. Jr.
A
reassessment of the effects of oropharyngeal anesthesia in
exercise-induced asthma.
Amer Rev Resp Dis 122: 381-386, 1980.

50. Fanta, C.H., McFadden, E.R. Jr., and Ingram, R.H. Jr.
Effects of
cromolyn sodium on the response to respiratory heat loss in normal
subjects.
Amer Rev Resp Dis 123: 161-164, 1981.

51. Ferguson, A., Addington, W., and Gaensler, E.A.
Dyspnea and
bronchospasm from inappropriate post-exercise hyperventilation.
Ann Int Med 71: 1063-1072, 1969.

68
52.

Ferris, L., Anderson, S., and Temple, D.
Histamine release in
exercise-induced asthma.
Brit Med J 1: 1697-1698, 1978.

53.

Field, J., Allegra, J., Trautlein, J., Demers, L., Gillin, M., and
Zelis, R.
Measurement of plasma prostaglandins during exerciseinduced bronchospasm.
J Allergy Clin Immunol 58: 581-585, 1976.

54.

Fish, J.E., Ankin, M.G., Adkinson, N.F. Jr., and Peterman, V.I.
Indomethacin modification of immediate-type immunologic airway
responses in allergic asthmatic and non-asthmatic subjects.
Evidence for altered arachidonic acid metabolism in asthma.
Amer
Rev Resp Dis 123: 609-614, 1981.

55.

Fisher, H.K., Holton, P., Buxton, R.St.J., and Nadel, J.A.
Resistance to breathing during exercise-induced asthma attacks.
Amer Rev Resp Dis 101: 885-896, 1970.

56. Fitch, K. and Morton, A.
Specificity of exercise in exerciseinduced asthma.
Brit Med J 4: 577-581, 1971.

57. Flower, R., Gryglewski, R., Herbaczynska-Cedro, K., and Vane. J.R.
Effects of anti-inflammatory drugs on prostaglandin biosynthesis.
Nature New Biology 238: 104, 1972.

58. Floyer, J.

A Treatise of the Asthma.

R. Wilkin (London) 1698.

59. Folco, G., Hansson, G., and Grastrom, E.
Leukotriene C4 stimulates
TxA2 formation in isolated sensitized guinea pig lungs.
Biochem
Pharmacol 30:2493, 1981.

60. Gardiner, P.J.
The effects of some natural prostaglandins on
isolated human cirular bronchial muscle.
Prostaglandins 10:
607-616, 1975.

61. Godfrey, S.
Exercise-induced asthma: clinical, physiological, and
therapeutic implications.
J Allergy Clin Immunol 56: 1-17, 1975.

62. Godfrey, S. and Konig, P.
Inhibition of exercise-induced asthma by
different pharmacological pathways.
Thorax 31: 137-143, 1976.

69
63. Granerus, G., Simonsson, B., Skoogh, B.E., et al.
Exercise-induced
bronchoconstriction and histamine release.
Scand J Resp Dis 52:
131-136, 1971.

64. Green, K., Hedqvist, P., and Svanborg, N.
Increased plasma levels
of 15-keto-13,14 dihydroprostaglandin F2< after allergen provoked
asthma in man.
Lancet 2: 1419-1421, 1974.

65. Grieco, M.H. and Pierson, R.N. Jr.
Mechanism of
bronchoconstriction due to beta adrenergic blockade: studies with
practolol, propranolol, and atropine.
J Allergy Clin Immunol 48:
143-152, 1971.

66. Griffin, M.P., McFadden, E.R. Jr., Ingram, R.H. Jr., and Pardee, S.
A controlled analysis of the effects of inhaled lignocaine in
exercise-induced asthma.
Thorax 37: 741-745, 1982.

67. Griffiths, J., Leung, F.Y., Gryzbowski, S., Moira, M.W., and ChanYeung, M.B.
Sequential estimation of plasma catecholamines in
exercise induced asthma.
Chest 62: 527-533, 1972.

68. Guirgis, H.
Anti anaphylactic effect of vitamin C in the guineapig.
J Pharm Pharmacol 17: 387, 1965.

69. Hafez, F.F.
and Crompton, G.K.
The forced expiratory volume after
hyperventilation in bronchitis and asthma.
Brit J Dis Chest 62:
41-45, 1968.

70. Hamberg, M., Heqvist, P., Strandberg, K., Svensson, J., and
Samuelsson, B.
Prostaglandin endoperoxides.
IV. Effects on smooth
muscle.
Life Sci 16: 451-462, 1975.

71. Hardy, C.C., Robinson, C., Tattersfield, A.E., andHolgate, S.T.
The bronchoconstrictor effect of inhaled prostaglandin D2 in normal
and asthmatic men.
N Engl J Med 311: 209-213, 1984.

72. Harries, M.G., Parkes, P.E.G., Lessof, M.H., and Orr, T.S.C.
Role
of bronchial irritant receptors in asthma.
Lancet 1: 5-7, 1981.

73. Haynes, R.L., Ingram, R.H. Jr., and McFadden, E.R. Jr.
An
assessment of the pulmonary response to exercise and an analysis of
the factors influencing it.
Amer Rev Resp Dis 114: 739-752, 1976.

70
74. Henderson, W.R., Shelhamer, J.H., Reingold, D.B., Smith, L.J.,
Evans, R. Ill, and Kaliner, M.
Alpha-adrenergic hyper¬
responsiveness in asthma.
Analysis of vascular and pupillary
responses.
N Engl J Med 300: 642-647, 1979.

75. Herxheimer, H.

Hyperventilation asthma.

76. Higgins, C. and Braunwald, E.
92-112, 1972.

Lancet 1: 82-87,

The prostaglandins.

1946.

Amer J Med 53:

77. Holroyde, M.C., Altounyan, R.E.C., Cole, M., Dixon, M., and
Elliott, E.V.
Bronchoconstriction produced in man by leukotrienes
C and D.
Lancet 2: 17-18, 1981.

78. Hunt, H.
1938.

Ascorbic acid in bronchial asthma.

Brit Med J 1: 726,

79.

James, L., Faciane, J., and Sly, R.M.
Effect of treadmill exercise
on asthmatic children.
J Allergy Clin Immunol 57: 408-416, 1976.

80.

Jones, R.S.
Assessment of respiratory function in the asthmatic
child.
Brit Med J 2: 972-975, 1966.

81.

Jones, R.S.
Significance of beta-blockade on ventilatory function
in normal and asthmatic subjects.
Thorax 27: 572, 1972.

82. Jones, R.S., Buston, M.J., and Wharton, M.J.
The effect of
exercise on ventilatory function in the child with asthma.
Brit J
Dis Chest 56: 78, 1962.

83. Jones, R.S., Wharton, M.J., and Buston, M.J.
The place of physical
exercise and bronchodilator drugs in the assessment of the
asthmatic child.
Arch Dis Child 38: 539, 1963

84. Kaliner, M.
Human lung tissue and anaphylaxis.
I. The role of
cyclic GMP as a modulator of the immunologically induced secretory
process.
J Allergy Clin Immunol 60: 204-211, 1977.

.

85

Kaliner, M., Orange, R.P., and Austen, K.F.
Immunological release
of histamine and slow reacting substance of anaphylaxis from human
lung.
IV. Enhancement by cholinergic and alpha adrenergic
stimulation.
J Exp Med 136: 556-567, 1972.

71

.

86

Karim,
Sandler, M., and Williams, E.D.
Distribution of
prostaglandins in human tissues.
Br J Pharmacol Chemother 31:
340-344, 1967.

87. Kiviloog, J.
Bronchial reactivity to exercise and methacholine in
bronchial asthma.
Scand J Resp Dis 54: 347-358, 1973.

88. Kiviloog, J., Irnell, L., and Eklund, G.
Ventilatory capacity,
working capacity and exercise-induced bronchoconstriction in a
population sample of subjects with bronchial asthma or chronic
bronchitis.
Scand J Resp Dis 56: 73, 1975.

89. Kordansky, D., Rosenthal, R.R., and Norman, P.S.
The effect of
vitamin C on antigen-induced bronchospasm.
Proc Amer Congr Allergy
Immunol, 1977 (Abst. 143).

90. Kordansky, D.V., Rosenthal, R.R., and Norman, P.S.
The effects of
vitamin C on antigen-induced bronchospasm.
J Allergy Clin Immunol
63: 61, 1979.

91. Kreissman, H., Mitchell, C., and Bouhuys, A.
Inhibition of
histamin-induced airway constriction.
Negative results with
oxtriphylline and ascorbic acid.
Lung 154: 223-229, 1977.

92. Kunos, G.
Reciprocal changes in alpha- and beta-adrenoceptor
reactivity myth or reality? Trends Pharmacol Sci 1: 282-284, 1980.

93. Lands, W., Lee, R., and Smith, W.
Factors regulating the
biosynthesis of various prostaglandins.
Ann NY Acad Sci 180:
107-122, 1971.

94. Lee, T.H., Assoufi, B.K., and Kay, A.B.
The link between exercise,
respiratory heat exchange, and the mast cell in bronchial asthma.
Lancet 1: 520-522, 1983.

95. Lee, T.H., Brown, M.J., Nagy, L., Causon, R., Walport, M.J., and
Kay, A.B.
Exercise-induced release of histamine and neutrophil
chemotactic factor in atopic asthmatics.
J Allergy Clin Immunol
70: 73-81, 1982.
( = Lee, 1982a).

■

72
96.

Lee, T.H., Nagy, L., Nagakura, T., Walport, M.J., and Kay, A.B.
Identification and partial characterization of an exercise-induced
neutrophil chemotactic factor in bronchial asthma.
J Clin Invest
69: 889-899, 1982.
( = Lee, 1982b).

97.

Leung, H.W. and Morrow, P.E.
Interaction of glutathione and
ascorbic acid in guinea pig lungs exposed to nitrogen dioxide.
Comm Chem Pathol Pharmac 31:111, 1981.

Res

98. Lewis, R.A., Austen, K.F., Drazen, J.M., Clark, D.A., Marfat, A.
and Corey, E.J.
Slow reacting substance of anaphylaxis:
Identification of C-l from D from human and rat sources.
Proc Nat
Acad Sci 77: 3710, 1980.

99. Lewis, R.A., Soter, N.A., Diamond, P.T., Austen, K.F., Oates, J.A.,
and Roberts, L.J. II.
Prostaglandin D2 release after activation of
rat and human mast cells with anti-Ig E.
J Immunol 129: 1627-1631,
1982.

100. Lloyd, T.
Bronchoconstriction in man following single deep
inspirations.
J Appl Physiol 18: 114-116, 1963.

101. Mathe, A.A. and Hedqvist, P.
Effects of prostaglandins F2« and E2
on airway conductance in healthy subjects and asthmatics.
Amer Rev
Resp Dis 111: 313-320, 1975.

102. Mathe, A.A., Hedqvist, P., Holmgron, A., and Svanborg, N.
Bronchial hyperreactivity to prostaglandin F2ac and histamine in
patients with asthma.
Brit Med J 1: 193-196, 1973.

103. McFadden, E.R. Jr.
An analysis of exercise as a stimulant for the
production of airway obstruction.
Lung 159: 3-11, 1981.

104. McFadden, E.R. Jr., Denison, D.M., Waller, J.F., Assoufi, B.,
Peacock, A., and Sopwith, T.
Direct recordings of the temperatures
in the tracheobronchial tree in normal man.
J Clin Invest 69:
700-705, 1982.

105. McFadden, E.R. Jr. and Ingram, R.H. Jr.
Exercise-induced airway
obstruction.
Ann Rev Physiol 45: 453-463, 1983.

73
106. McFadden E.R. Jr., Ingram, R.H. Jr., Haynes, R.L., and Wellman,
J.J.
Predominant site of flow limitation and mechanisms of postexertional asthma.
J Appl Physiol 42: 746-752, 1977.
( =
McFadden, 1977b).

107. McFadden, E.R. Jr., Stearns, D.R., Ingram, R.H. Jr., and Leith,
D.E.
Relative contributions of hypocapnia and hyperpnea as
mechanisms in postexercise asthma.
J Appl Physiol 42: 22-27, 1977.
( = McFadden, 1977a).

108. McNally, J.F., Enright, P., Hirsch, J.E., and Souhrada, J.F.
The
attenuation of exercise-induced bronchoconstriction by
oropharyngeal anesthesia.
Amer Rev Resp Dis 119: 247-252, 1979.

109. McNeill, R.S., Nairn, J.R., Millar, J.S., and Ingram, C.G.
Exercise-induced asthma.
Q. J. Med. 35: 55-67, 1966.

110. Mohsenin, V., DuBois, A.B., and Douglas, J.S.
Effect of ascorbic
acid on response to methacholine challenge in asthmatic subjects.
Amer Rev Resp Dis 127: 143-147, 1983.

111. Morris, H.R., Taylor, G.W., Piper, P.J., and Tippens, J.R.
Structure of slow reacting substance of anaphylaxis from guinea pig
lung.
Nature 285: 104, 1980.

112. Muccitelli, R.M., Osborn, R.R., and Weichman, B.M.
Effect of
inhibition of thromboxane production on the leukotriene D4-mediated
bronchoconstriction in the guinea pig.
Prostaglandins 26: 197-206,
1983.

113. Murphy, R.C., Hammarstrom, S., and Samuelsson, B.
Leukotriene C: a
slow reacting substance (SRS) from murine mouse mastocytoma cells.
Proc Nat Acad Sci 76: 4275, 1979.

114. Nadel, J.
and Tierney, D.
Effect of a previous deep inspiration
on airway resistance in man.
J Appl Physiol 16: 717-719, 1961.

115. Newball, H.H.
Effects of chemical mediators on asthmatic airways.
In:
Lung Cells in Disease.
Bouhuys, A. editor.
Elsevier/NorthHolland Biomedical Press 1976, pp. 261-264.

74
116. Newball, H.H., Adkinson, N.F. Jr., Adams, G.K., Findlay, S.R., and
Lichtenstein, L.M.
Mechanisms of anaphylactic release of
prostaglandins (PGs) from human lung.
J Allergy Clin Immunol 61:
148, 1978.

117. Newball, H.H., Reiser, H.R., and Lenfant, C.J.
functions as a local hormone on human airways.
183-197, 1980.

Prostaglandin F2
Respir Physiol 41:

118. Newball, H.H. and Lenfant, C.J.
The influence of atropine and
cromolyn on human bronchial hyperreactivity to aerosolized
prostaglandin F2°<.
Respir Physiol 30: 125-136, 1977.

119. Ogilvy, C.S., DuBois, A.B., and Douglas, J.S.
Effects of ascorbic
acid and indomethacin on the airways of healthy male subjects with
and without induced bronchoconstriction.
J Allergy Clin Immunol
67: 363-369, 1981.

120. Orange, R.P. and Austen, K.F.
Slow reacting substance of
anaphylaxis.
Adv Immunol 10: 105-144, 1969.

121. Orange, R.P., Kaliner, M.A., Laraia, P.J., et al.
Immunological
release of histamine and slow reacting substance of anaphylaxis
from human lung. II. Influence of cellular levels of cyclic AMP.
Fed Proc 30: 1725-1729, 1971.

122. Orange, R.P., Murphy, R.C., Karnovsky, M.L., and Austen, K.F.
The
physicochemical characteristics and purification of slow reacting
substance of anaphylaxis.
J Immunol 110: 760, 1973.

123. Orange, R.P., Valentine, M., and Austen, K.F.
Inhibition of the
release of slow reacting substance of anaphylaxis in the rat with
diethylcarbamazine.
Proc Soc Exptl Biol Med 127: 127-32, 1968.

124. Patel, K.R.
Atropine, sodium cromoglycate, and thymoxamine in PGF2
-induced bronchoconstriction in extrinsic asthma.
Brit Med J 2:
360-362, 1975.

125. Patel, K.R.
Calcium antagonists in exercise-induced asthma.
Med J 282: 932-933, 1981.

Brit

'

75
126. Patel, K.R. and Kerr, J.W.
The airways response to phenylephrine
after blocking of alpha and beta receptors in extrinsic bronchial
asthma.
Clin Allergy 3: 439-448, 1973.

127. Patel, K.R., Kerr, J.W., MacDonald, E.B., et al.
The effect of
thymoxamine and cromalyn sodium on postexercise bronchoconstriction
in asthma.
J Allergy Clin Immunol 57: 285-292, 1976.

128. Peters, S.P., MacGlashan, D.W. Jr., Schulman, E.S., Schleimer,
R.P., and Lichtenstein, L.M.
The production of arachidonic acid
(AA) metabolites by purified human lung mast cells (HMC).
Fed Proc
42: 1375, 1983.

129. Pierson, W.E., Bierman, C.W., and Stamm, S.J.
Cycloergometerinduced bronchospasm.
J Allergy Clin Immunol 43: 136, 1969.

130. Piper, P.J. and Samhoun, M.N.
The mechanism of action of
leukotriene C4 and D4 in guinea pig isolated perfused lung and
parenchymal strips of guinea pig, rabbit, and rat.
Prostaglandins
21: 793, 1981.

131. Piper, J.P. and Walker, J.C.
The release of spasmogenic substances
from human chopped lung tissue and its inhibition.
Brit J
Pharmacol 47: 291-304, 1973.

132. Platshon, L.F. and Kaliner, M.
The effects of the immunologic
release of histamine upon human lung cyclic nucleotide levels and
prostaglandin synthesis.
J Clin Invest 62: 1113-1121, 1978.

133. Pride, N.B.
The assessment of airflow obstruction.
Chest 65:135, 1971.

Brit J Dis

134. Prime, F.J., Bianco, S., Griffin, J.P., et al.
The effects on
airways conductance of alpha-adrenergic stimulation and blocking.
Bull Physiopathol Respir 8: 99-109, 1972.

135. Puglisi, L., Berti, F., Bossio, E., Longiave, D., and Nicosia, S.
Ascorbic acid and PGF2 antagonism on tracheal smooth muscle.
In:
Advances in Prostaglandins and thromboxane research.
Samuelsson,
B. and Paoletti, R. editors.
Raven Press (New York) 1976, pp.
503-506.

76
136. Puglisi, L. and Maggi, F.
Respiratory system.
In:
Prostaglandins
and Thromboxanes.
Berti, F. editor.
Plenum (New York) 1977, pp.
150-154.

137. Rasmussen, F.V., Madsen, L., and Bundgaard, A.
Combined effect of
an anticholinergic drug ipratropium bromide and disodium
cromoglycate in exercise-induced asthma.
Scand J Resp Dis (suppl.)
103: 159-163, 1979.

138. Reed, C.E.
Abnormal autonomic mechanisms in asthma.
Clin Immunol 53: 34-41, 1974.

139. Reisseissen, F.D.

De pulmonis structura.

Strasbourg,

J Allergy

1803.

140. Rothberg, K.G. and Hitchcock, M.
Effects of ascorbic acid
deficiency on the in vitro biosynthesis of cyclooxygenase
metabolites in guinea pig lungs.
Prostaglandins Leuk Med 12:
137-147, 1983.

141. Rudolph, M., Grant, B.J.B., Saunders, K.B., Brostoff, J., Salt,
P.J., and Walker, D.I.
Aspirin in exercise-induced asthma
(letter).
Lancet 1: 450, 1975.

142. Salter, H. H.
On Asthma: Its Pathology and Treatment.
and Lea (Philadelphia) 1864, pp. 132-153.

Blanchard

143. Samuelsson, B.
Advances in Pharmacology and Therapeutics II.
Yoshida, H., Hagihara, Y., and Ebashi, S. editors.
Pergamon (New
York) 1982, pp. 55-75.

•144. Schachter, E.N., Kreisman, H., and Bouhuys, A.
Prostaglandinsynthesis inhibition and exercise bronchospasm (letter).
Ann Int
Med 89: 287-288, 1978.
( = Schachter, 1978b).

145. Schachter, E.N., Kreisman, H., Littner, M., Beck, G.J., and
Voncken, F.
Airway responses to exercise in mild asthmatics.
J
Allergy Clin Immunol 61: 390-398, 1978.
( = Schachter, 1978a).

146. Schachter, E.N. and Rubin, M.
The effect of an aerosolized
antihistamine on exercise induced bronchospasm.
Ann Allergy (in
press).

77
147. Schachter, E.N. and Schlesinger, A.
The attenuation of exerciseinduced bronchospasm by ascorbic acid.
Annals of Allergy 49:
146-151, 1982.

148. Schianterelli, P., Bongrani, S., and Folco, G.
Bronchospasm and
pressor effects induced in the guinea pig by leukotriene C4 are
probably due to release of cyclooxygenase products.
Eur J
Pharmacol 73: 363, 1981.

149. Schlesinger, A.
Attenuation of exercise-induced bronchospasm by
ascorbic acid.
M.D. thesis, Yale University School of Medicine,
1980.

150. Schulman, E.S., Adkinson, N.F. Jr., Adams, G.K., Lichtenstein,
L.M., and Newball, H.H.
Anaphylactic release of thromboxane A-2
from human bronchi and parenchyma.
J Allergy and Clin Immunol 65:
235, 1980.
( = Schulman, 1980a).

151. Schulman, E.S., Adkinson, N.F. Jr., Demers, L.M., et al.
Anaphylactic release of prostaglandins, thromboxane A-2, and
prostacyclin from human lung.
Fed Proc 39:931, 1980.
( =
Schulman, 1980b).

152. Schulman, E.S., Newball, H.H., Demers, L.M., Fitzpatrick, F.A., and
Adkinson, N.F. Jr.
Anaphylactic release of thromboxane A2,
prostaglandin D2, and prostacyclin from human lung parenchyma.
Amer Rev Resp Dis 124: 402-406, 1981.

153. Seaton, A., Davies, G., Gaziano, D., and Hughes, R.O.
induced asthma.
Brit Med J 3: 556-558, 1969.

Exercise-

154. Shaw, J. and Moser, K.
The current status of prostaglandins in the
lung.
Chest 1: 75-80, 1975.

155. Sheppard, D.J., Epstein, J., Holtzman, M.J., Nadel, J.A., and
Boushey, H.A.
Dose-dependent inhibition of cold air-induced
bronchoconstriction by atropine.
J Appl Physiol 53: 169-174, 1982.

156. Sheppard, D.J., Nadel, J.A., and Boushey, H.A.
Inhibition of
sulfur dioxide-induced bronchoconstriction by disodium cromoglycate
in asthmatic subjects.
Amer Rev Resp Dis 124: 257-259, 1981.

78
157. Shiner, R.J., and Molho, M.I.
Comparison between an alphaadrenergic antagonist and a beta2-adrenergic agonist in bronchial
asthma.
Chest 83: 602-606, 1983.

158. Silverman, M., Anderson, S.D., and Walker, S.R.
preceding exercise-induced bronchoconstriction.
207-209, 1972.
( = Silverman, 1972a).

Metabolic changes
Brit Med J 1:

159. Silverman, M.
and Andrea, T.
Time course of effect of disodium
cromoglycate on exercise induced asthma.
Arch Dis Child 47:
419-422, 1972.
( = Silverman, 1972b).

160. Simonsson, B.G., Skoogh, B.E., and Ekstrom-Jodal, B.
Exerciseinduced airways constriction.
Thorax 27: 169-180, 1972.
( =
Simonsson, 1972a).

161. Simonsson, B.G., Svedmyr, N., and Skoogh, B.E.
In vivo and in
vitro studies on alpha-receptors in human airways: potentiation
with bacterial endotoxin.
Scand J Resp Dis 53: 227-231, 1972.
( =
Simonsson, 1972b).

162. Sly, R.M.
Exercise-related changes in airway obstruction:
frequency and clinical correlates in asthmatic children.
Ann
Allergy 28: 1-16, 1970.

163. Sly, R.M.
Effect of diethylcarbamazine pamoate upon exerciseinduced bronchospasm.
J Allergy Clin Immunol 53: 82-83, 1974.
Sly, 1974a).

( =

164. Sly, R.M. and Matzen, K.
The effect of diethylcarbamazine pamoate
upon exercise-induced obstruction in asthmatic children.
Ann
Allergy 33: 138-144, 1974.
( = Sly, 1974b).

165. Smith, A.P.
Effect of indomethacin in asthma: evidence against a
role for prostaglandins in its pathogenesis.
Brit J Clin Pharmacol
2: 307-309, 1975.
( = Smith, 1975c).

166. Smith, A.P. and Cuthbert, M.F.
Effects of inhaled prostaglandins
on bronchial tone in man.
In:
Advances in the Biosciences, Vol 9.
Bergstrom, S. and Bernhard, S. editors.
Pergamon Press (New York)
1973, p.213.

79
167. Smith, A.P., Cuthbert, M.F., and Dunlop, L.S.
Effects of inhaled
prostaglandins E-l, E-2, and F-2 on the airway resistance of
healthy and asthmatic man.
Clin Sci Mol Med 48: 421-430, 1975.
(
= Smith, 1975a).

168. Smith, A.P. and Dunlop, L.
Prostaglandins and asthma (letter).
Lancet 1: 39, 1975.
( = Smith, 1975b).

169. Snedecor, G.W. and Cochran, W.G.
Statistical Methods.
Sixth
edition.
Iowa State Univ Press (Ames, Iowa) 1967, pp. 91-116.

170. Soter, N.A. and Austen, K.F.
Urticaria, angioedema, and mediator
release in humans in response to physical environment stimuli.
Fed
Proc 36: 1736-1740, 1977.

171. Souza, L.M. and Silverman, M.
Prostaglandins in exercise-induced
asthma (letter).
Clin Allergy 11: 506-507, 1981.

172. Spector, S.L.
Alpha-adrenergic antagonists in asthmatic patients:
a note of caution.
N Engl J Med 301: 388-389, 1979.

173. Stanescu, D.C., and Teculescu, D.B.
Exercise and cough-inducedasthma.
Respiration 27: 377-379, 1970.

174. Strandberg, K., Mathe, A.A., and Yen, S.S.
Release of histamine
and formation of prostaglandins in human lung tissue and rat mast
cells.
Int Arch Allergy Appl Immunol 53: 520-529, 1977.

175. Strauss, R.H., Ingram, R.H. Jr., and McFadden, E.R. Jr.
A critical
assessment of the roles of circulating hydrogen ion and lactate in
the production of exercise-induced asthma.
J Clin Invest 60:
658-664, 1977.
( = Strauss, 1977a).

176. Strauss, R.H., McFadden, E.R. Jr., Ingram, R.H. Jr., Deal, E.C.
Jr., and Jaeger, J.J.
Influence of heat and humidity on the airway
obstruction induced by exercise in asthma.
J Clin Invest 61:
433-440, 1978.

177. Strauss, R.H., McFadden, E.R. Jr., Ingram, R.H. Jr., and Jaeger,
J.J.
Enhancement of exercise-induced asthma by cold air.
N Engl J
Med 297: 743-747, 1977.
( = Strauss, 1977b).

80
178. Subramanian, N.
Histamine degradative potential of ascorbic acid:
Considerations and evaluations.
Agents Actions 8: 484, 1978.

179. Svensson, J., Strandberg, K., Tuvemo, T., and Hamberg, M.
Thromboxane A-2: effects on airway and vascular smooth muscle.
Prostaglandins 14: 425-436, 1977.

180. Sweatman, W.J.F. and Collier, H.O.J.
Effects of prostaglandins on
human bronchial muscle.
Nature 217:69, 1968.

181. Szczeklik, A., Gryglewski, R.J., and Czerniawaska-Mysik, G.
Relationship of inhibition of prostaglandin biosynthesis by
analgesics to asthma attacks in aspirin-sensitive patients.
Med J 1: 67-69, 1975.

Brit

182. Szczeklik, A. and Nizankowska, E.
Asthma improved by aspirin-like
drugs.
Brit J Dis Chest 77: 153-158, 1983.

183. Szentivanyi, A. and Fischel, C. W.
The beta adrenergic theory and
cyclic AMP-mediated control mechanisms in human asthma.
In:
Bronchial Asthma: Mechanisms and therapeutics.
Edited by E.B.
Weiss and M.S. Segal.
Little, Brown (Boston) 1976, pp. 137-154.

184. Tauber, F.I., Kaliner,
Immunologic release of
anaphylaxis from human
release of histamine.

M., Stechschulte, D.J., and Austen, K.F.
histamine and slow reacting substance of
lung.
V. Effects of prostaglandins on
J Immunol 111: 27-32, 1973.

185. Thomson, N.C., Patel, K.R., and Kerr, J.W.
Sodium cromoglycate and
ipratropium bromide in exercise-induced asthma.
Thorax 33:
694-699, 1978.

186. Valentine, M.
Chemical mediators in asthma.
In:
Bronchial
Asthma.
Weiss, E. and Segal, M. editors.
Little, Brown (Boston)
1976, p.182.

187. Valic, F. and Zuskin, E.
Pharmacologic prevention of acute
ventilatory capacity reduction in flax dust exposure.
Br J Ind Med
30: 381, 1973.

188. Vane, J.R.
Inhibition of prostaglandin synthesis as a mechanism of
action for aspirin-like drugs.
Nature New Biology 231: 232-235,
1971.

81
189. Van Wauwe, J. and Goossenz, J.
Effects of antioxidants on
cyclooxygenase and lipoxygenase activities in intact human
platelets: Comparison with indomethacin and ETYA.
Prostaglandins
26: 725-730, 1983.

190. Vassallo, C.L., Gee, J.B.L., and Domm, B.M.
Exercise-induced
asthma: observations regarding hypocapnia and acidosis.
Amer Rev
Resp Dis 105: 42-49, 1972.

191. Walters, E.H.
Prostaglandins and the control of airways responses
to histamine in normal and asthmatic subjects.
Thorax 38: 188-194,
1983.

192. Wasserman,
urticaria.
chemotactic
challenge.

S.I., Soter, N.A., Center, D.M., and Austen, K.F.
Cold
Recognition and characterization of a neutrophil
factor which appears in serum during experimental cold
J Clin Invest 60: 189-196, 1977.

193. Webb-Johnson, D.C. and Andrews, J.L. Jr.
Bronchodilator therapy.
N Engl J Med 297: 476-482 and 758-764, 1977.

194. Weichman, B.M., Wasserman, M.A., and Gleason, J.G.
SK&F 88046: A
unique pharmacological antagonist of bronchoconstriction induced by
leukotriene D4, thromboxane, and prostaglandins F2
and D2 in
vitro.
J Pharmacol Exptl Ther 228: 128-132, 1984.

195. Weiler-Ravell, D. and Godfrey, S.
Do exercise- and antigen-induced
asthma utilize the same pathways? Antigen provocation in patients
rendered refractory to exercise-induced asthma.
J Allergy Cli
Immunol 67: 391-397, 1981.

196. Weiss, J.W., Drazen, J.M., Coles, N. et al.
Bronchoconstrictor
effects of leukotriene C in humans.
Science 216: 196-198, 1982.

197. Wilson, N.M., Barnes, P.J., Vickers, H., and Silverman, M.
Hyperventilation-induced asthma: evidence for two mechanisms.
Thorax 37: 657-662, 1982.

198. Zuskin, E., Lewis, A.J., and Bouhuys, A.
Inhibition of histamineinduced airway constriction by ascorbic acid.
J Allergy Clin
Immunol 51: 218-226, 1973.

199. Zuskin, E., Valic, F., and Bouhuys, A.
Byssinosis and airways
responses due to exposure to textile dust.
Lung 154: 17, 1976.

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master's and Doctor’s degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, tut passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

